Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1-benzyl-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl)acetic acid
-
35% inhibition at 0.001 mM
(2E)-2-(2,5-bis[2-[4-(trifluoromethyl)phenyl]ethoxy]benzylidene)hexanoic acid
-
-
(2E)-2-(2,5-bis[[4-(trifluoromethyl)benzyl]oxy]benzylidene)hexanoic acid
-
55.1% residual activity at 0.01 mM
(2E)-2-[2,5-bis(2-cyclohexylethoxy)benzylidene]hexanoic acid
-
-
(2E)-2-[2,5-bis(2-phenylethoxy)benzylidene]hexanoic acid
-
-
(2E)-2-[4-[3-(2,3-dimethylphenoxy)propoxy]benzylidene]hexanoic acid
-
28.3% residual activity at 0.01 mM
(2E)-2-[5-(2-cyclohexylethoxy)-2-[[4-(trifluoromethyl)benzyl]oxy]benzylidene]hexanoic acid
-
74% residual activity at 0.01 mM
(2R)-2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
(2S)-2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
(3R)-1-(7-chloro-2-[2-chloro-5-[(2-methylpropanamido)methyl]phenyl]-4-oxo-3,4-dihydroquinazolin-6-yl)pyrrolidin-3-yl acetate
-
(3S)-1-(7-chloro-2-[2-chloro-5-[(2-methylpropanamido)methyl]phenyl]-4-oxo-3,4-dihydroquinazolin-6-yl)pyrrolidin-3-yl acetate
-
(4-dodecanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)acetic acid
-
22% inhibition at 0.001 mM
(4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl)acetic acid
-
17% inhibition at 0.001 mM
(4E)-4-[2-(3-bromophenyl)hydrazin-1-ylidene]-1-ethanethioyl-3-methyl-4,5-dihydro-1H-pyrazol-5-one
-
-
(4R)-1-(8-chloroquinolin-2-yl)-N-[cis-4-(hydroxymethyl)cyclohexyl]-3,3-dimethylpiperidine-4-carboxamide
-
-
(4R)-N-[(1S,3S)-3-(hydroxymethyl)cyclohexyl]-3,3-dimethyl-1-[4-(trifluoromethyl)phenyl]piperidine-4-carboxamide
-
-
(4S)-1-(8-chloroquinolin-2-yl)-N-[cis-4-(hydroxymethyl)cyclohexyl]-3,3-dimethylpiperidine-4-carboxamide
-
-
(4S)-3,3-dimethyl-1-(8-methylquinolin-2-yl)-N-[(3S)-oxan-3-yl]piperidine-4-carboxamide
-
-
(4S)-3,3-dimethyl-1-(8-methylquinolin-2-yl)-N-[(3S)-oxolan-3-yl]piperidine-4-carboxamide
-
-
(4S)-3,3-dimethyl-N-(3-methylbutan-2-yl)-1-(8-methylquinolin-2-yl)piperidine-4-carboxamide
-
-
(4S)-N-[(1S,3S)-3-(hydroxymethyl)cyclohexyl]-3,3-dimethyl-1-[4-(trifluoromethyl)phenyl]piperidine-4-carboxamide
-
-
(4S)-N-[(3S)-3-(hydroxymethyl)cyclohexyl]-3,3-dimethyl-1-(8-methylquinolin-2-yl)piperidine-4-carboxamide
-
-
([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)(5,8-dihydronaphthalen-1-yl)acetic acid
-
-
([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)acetic acid
-
75.4% residual activity at 0.01 mM
1,5-anhydro-2,3,4-trideoxy-3-[[(4S)-3,3-dimethyl-1-(8-methylquinolin-2-yl)piperidine-4-carbonyl]amino]-D-glycero-hexitol
-
-
1-(7-chloro-2-[2-chloro-5-[(2-methylpropanamido)methyl]phenyl]-4-oxo-3,4-dihydroquinazolin-6-yl)-N-methylpiperidine-4-carboxamide
76% inhibition at 0.01 mM
1-benzyl-4-dodecanoyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid
-
65% inhibition at 0.001 mM
1-[2-(2-methylphenyl)ethyl]-4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1H-1,2,3-triazole
-
90% residual activity at 0.03 mM
1-[4-[2-(2-carboxy-2-methylpropyl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-4-yl]-2-fluorophenyl]pyridinium
-
-
1-[5-chloro-6-(4-chlorophenyl)-1,3-benzoxazol-2-yl]-N-[(1S,3S)-3-(hydroxymethyl)cyclohexyl]piperidine-4-carboxamide
1-[6-(4-chlorophenyl)-5-methyl-1,3-benzoxazol-2-yl]-N-[(1S,3S)-3-(hydroxymethyl)cyclohexyl]piperidine-4-carboxamide
-
-
11-oxo-beta-boswellic acid
-
-
15-deoxy-DELTA12,14-prostaglandin J2
-
-
2(4-(3-biphenyloxypropoxy)phenylthio)hexanoic acid
-
-
2-(2,3-diphenethoxybenzylidene)hexanoic acid
-
-
2-(2,6-dichloroanilino)-7,7-dimethyl-N-(2,2,2-trifluoroethyl)-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2,6-dichloroanilino)-7,7-dimethyl-N-(2,2,3,3,3-pentafluoropropyl)-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2,6-dichloroanilino)-7,7-dimethyl-N-phenyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2,6-dichloroanilino)-7,7-dimethyl-N-[4-(trifluoromethyl)phenyl]-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2,6-dichloroanilino)-7,7-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2,6-dichloroanilino)-7-methyl-N-[3-(trifluoromethyl)phenyl]-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2,6-dichloroanilino)-7-methyl-N-[4-(trifluoromethyl)phenyl]-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2,6-dichloroanilino)-N-(2,6-dimethylpyridin-3-yl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2,6-dichloroanilino)-N-(2-fluorophenyl)-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2,6-dichloroanilino)-N-(4,4-difluorocyclohexyl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2,6-dichloroanilino)-N-(4-fluorophenyl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2,6-dichloroanilino)-N-(6-methoxypyridin-3-yl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2,6-dichloroanilino)-N-[(4-fluorophenyl)methyl]-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2-chloro-6-fluoroanilino)-7,7-dimethyl-N-[4-(trifluoromethyl)phenyl]-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2-chloro-6-fluoroanilino)-N-(3-cyanophenyl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2-chloro-6-fluoroanilino)-N-(4-cyanophenyl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2-chloro-6-fluoroanilino)-N-(4-fluorophenyl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2-chloro-6-fluoroanilino)-N-(4-fluorophenyl)-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2-chloro-6-fluoroanilino)-N-(5-chloropyridin-2-yl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2-chloro-6-fluoroanilino)-N-(cyclohexylmethyl)-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2-chloro-6-fluoroanilino)-N-[3-fluoro-5-(trifluoromethyl)phenyl]-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2,3-e]benzimidazole-5-carboxamide
-
2-(2-chloro-6-fluoroanilino)-N-[6-(difluoromethoxy)pyridin-3-yl]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-(2-chloro-6-fluorophenyl)-4-(4-chlorophenyl)-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-(4-phenoxyphenyl)-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-(2-phenylethyl)phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylethynyl)phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylsulfonyl)phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-[(E)-2-phenylethenyl]phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-7-phenyl-1,5-dihydro-4H-naphtho[1,2-d]imidazol-4-one
-
2-(2-chloro-6-fluorophenyl)-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one
-
-
2-(3,5-diphenethoxybenzyl)hexanoic acid
-
-
2-(3,5-diphenethoxybenzylidene)hexanoic acid
-
-
2-(4-bromophenyl)-5-(2-chloro-6-fluorophenyl)-1H-imidazole
-
-
2-(4-dodecanoyl-3,5-dimethyl-1-phenylpyrrol-2-yl)acetic acid
-
23% inhibition at 0.001 mM
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)benzene-1,3-dicarbonitrile
2-(difluoromethyl)-5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)benzamide
-
-
2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]-N-[4-methyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]pyridine-3-carboxamide
2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]-N-[5-methyl-4-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]pyridine-3-carboxamide
2-(difluoromethyl)-N-(1H-imidazol-2-yl)-5-([[(2R)-2-methylbutanoyl]amino]methyl)benzamide
-
-
2-(difluoromethyl)-N-(1H-imidazol-2-yl)-5-[(2-methylpropanamido)methyl]benzamide
-
-
2-(difluoromethyl)-N-[4-methyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]-5-(propanamidomethyl)pyridine-3-carboxamide
-
-
2-(trifluoromethyl)-N-(3-[[5-(trifluoromethyl)pyridin-2-yl]carbamoyl]phenyl)benzamide
-
2-([4,6-bis[2-(4-cyanophenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
-
2-([4,6-bis[2-(4-methoxyphenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
63.7% residual activity at 0.01 mM
2-([4,6-bis[2-(4-methylphenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
-
2-([4,6-bis[2-(4-nitrophenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
-
2-([4,6-bis[2-(thiophen-3-yl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
-
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
2-([4-chloro-6-[(4'-cyanobiphenyl-4-yl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
2-([4-chloro-6-[(5-methoxy-2-methylbiphenyl-4-yl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
2-([4-[(biphenyl-4-ylmethyl)amino]-6-chloropyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(2-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
88.3% residual activity at 0.01 mM
2-([4-[3-(2-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(3-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
59.1% residual activity at 0.01 mM
2-([4-[3-(3-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
58% residual activity at 0.01 mM
2-([4-[3-(4-chloro-2-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(4-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(quinolin-6-yloxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-bromo-5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)benzamide
-
-
2-chloro-4-fluoro-N-(1H-imidazol-2-yl)-5-[(2-methylpropanamido)methyl]benzamide
-
CEP-32496
2-chloro-4-[(2,2-dimethylpropanamido)methyl]-N-[3-[4-(trifluoromethyl)anilino][1,2]thiazolo[4,5-b]pyridin-7-yl]benzamide
-
2-chloro-5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)benzamide
2-chloro-5-[(2,2-dimethylpropanamido)methyl]-N-[4-oxo-3-[4-(trifluoromethyl)phenyl]-3,4-dihydrophthalazin-6-yl]benzamide
-
2-chloro-5-[(3,3-dimethylbutanamido)methyl]-N-(1H-imidazol-2-yl)benzamide
-
-
2-chloro-6-fluoro-N-[3-[4-(trifluoromethyl)anilino][1,2]thiazolo[4,5-b]pyridin-7-yl]benzamide
-
2-chloro-N-(1H-imidazol-2-yl)-4-methyl-5-[(2-methylpropanamido)methyl]benzamide
-
-
2-chloro-N-(1H-imidazol-2-yl)-5-[(2-methylpropanamido)methyl]benzamide
-
-
2-chloro-N-[3-(naphthalen-1-ylcarbamoyl)phenyl]benzamide
-
selective for human over rat MPGES1
2-methyl-2-(cis-4-[[1-(3-methyl-5-phenylfuro[2,3-b]pyridin-6-yl)piperidine-4-carbonyl]amino]cyclohexyl)propanoic acid
-
-
2-[(3,5-dichloropyridin-4-yl)amino]-7,7-dimethyl-N-[4-(trifluoromethyl)phenyl]-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-[(3,5-dichloropyridin-4-yl)amino]-7-methyl-N-(3-methylbutyl)-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-[(3,5-dichloropyridin-4-yl)amino]-7-methyl-N-[4-(trifluoromethyl)phenyl]-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-[(3,5-dichloropyridin-4-yl)amino]-N-[(4-fluorophenyl)methyl]-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-[(3,5-dichloropyridin-4-yl)amino]-N-[2-fluoro-4-(trifluoromethyl)phenyl]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-[(3,5-dichloropyridin-4-yl)amino]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
2-[(3,5-diphenethoxyphenyl)thio]hexanoic acid
-
-
2-[(4,6-bis[2-[4-(trifluoromethoxy)phenyl]ethoxy]pyrimidin-2-yl)sulfanyl]hexanoic acid
-
88.3% residual activity at 0.01 mM
2-[(4,6-bis[2-[4-(trifluoromethyl)phenyl]ethoxy]pyrimidin-2-yl)sulfanyl]hexanoic acid
-
-
2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid
-
-
2-[(4-[3-[2-(propan-2-yl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
-
2-[(4-[3-[3-(propan-2-yl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
-
2-[(4-[3-[3-(trifluoromethyl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
-
2-[(4-[3-[4-chloro-3-(trifluoromethyl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
-
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]nonanoic acid
-
-
2-[2,3-bis(2-phenylethoxy)benzyl]hexanoic acid
-
-
2-[2,4-bis(2-phenylethoxy)benzyl]hexanoic acid
-
90.1% residual activity at 0.01 mM
2-[2,5-bis(2-phenylethoxy)benzyl]hexanoic acid
-
-
2-[2-(2-chloro-6-fluorophenyl)-4-[6-(phenylethynyl)pyridin-3-yl]-1H-imidazol-5-yl]ethanol
-
-
2-[2-chloro-5-[(2-methylpropanamido)methyl]phenyl]-4-oxo-3,4-dihydroquinazoline-7-carboxamide
16% inhibition at 0.01 mM
2-[2-[(1S,2S)-2-([1-[4-(trifluoromethoxy)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]benzoic acid
-
2-[2-[(1S,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]benzoic acid
-
2-[2-[(1S,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]pyridine-3-carboxylic acid
-
2-[2-[(1S,2S)-2-([1-[5-(trifluoromethyl)pyridin-2-yl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]benzoic acid
-
2-[2-[(1S,2S)-2-[[1-(8-methylquinolin-2-yl)piperidine-4-carbonyl]amino]cyclopentyl]ethyl]benzoic acid
-
2-[3,4-bis(2-phenylethoxy)benzyl]hexanoic acid
-
-
2-[3,5-bis(2-phenylethoxy)phenoxy]hexanoic acid
-
-
2-[3-(aminooxy)-2,2-dimethyl-3-oxopropyl]-3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indole
-
IC50: 0.01 mM
2-[4-(4-bromophenyl)-1H-imidazol-2-yl]benzonitrile
-
-
2-[4-(4-chlorophenyl)-1H-imidazol-2-yl]-3-fluorobenzonitrile
-
-
2-[4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)phenyl]propan-2-ol
-
-
2-[4-[3-(2,3-dimethylphenoxy)propoxy]benzyl]hexanoic acid
-
-
2-[6-(2-cyclopropylethoxy)-9-(3-hydroxy-3-methylbutyl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid
-
licofelone, ML3000
2-[6-bromo-9-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
2-[6-chloro-9-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
2-[6-chloro-9-(3-hydroxy-3-methylbutyl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
2-[[4,6-bis(2-cycloheptylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
62.4% residual activity at 0.01 mM
2-[[4,6-bis(2-cyclohexylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4,6-bis(2-cyclopentylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
90% residual activity at 0.01 mM
2-[[4,6-bis(2-cyclopropylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]butanoic acid
-
-
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]octanoic acid
-
-
2-[[4,6-bis(3-methylbutoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
54.5% residual activity at 0.01 mM
2-[[4,6-bis(3-phenylpropoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4,6-bis(4-phenylbutoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4,6-bis(benzyloxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4-(3-phenoxypropoxy)phenyl]sulfanyl]hexanoic acid
-
81.9% residual activity at 0.01 mM
2-[[4-(biphenyl-4-ylamino)-6-chloropyrimidin-2-yl]sulfanyl]nonanoic acid
-
-
3-(1,3,5-trimethyl-4-octadecanoyl-1H-pyrrol-2-yl)propanoic acid
-
97% inhibition at 0.001 mM
3-(1,3,5-trimethyl-4-tetradecanoyl-1H-pyrrol-2-yl)propanoic acid
-
91% inhibition at 0.001 mM
3-(1-benzothiophen-2-yl)-2-bromo-5-hydroxycyclopent-2-en-1-one
-
-
3-(1-benzyl-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl)propanoic acid
-
62% inhibition at 0.001 mM
3-(1-benzyl-4-dodecanoyl-5-methyl-3-phenylpyrrol-2-yl)propionic acid
-
64% inhibition at 0.001 mM
3-(4-bromophenyl)-5-(2-chloro-6-fluorophenyl)-1H-1,2,4-triazole
-
-
3-(4-dodecanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid
-
54% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)-N-(benzenesulfonyl)propanamide
-
77% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)-N-(methanesulfonyl)propanamide
-
52% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)propanamide
-
39% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)propanehydrazide
-
35% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)propanenitrile
-
22% inhibition at 0.001 mM
3-(4-dodecanoyl-1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)propanoic acid
3-(4-dodecanoyl-3,5-dimethyl-1-phenylpyrrol-2-yl)propionic acid
-
65% inhibition at 0.001 mM
3-(4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl)propanoic acid
-
38% inhibition at 0.001 mM
3-(4-hexadecanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid
-
97% inhibition at 0.001 mM
3-(naphthalen-1-ylamino)-6-nitrobenzo[d]isothiazole 1,1-dioxide
-
-
3-O-acetyl-28-hydroxylupeolic acid
-
31.1% residual activity at 0.01 mM
3-O-acetyllupeolic acid
-
51.4% residual activity at 0.01 mM
3-O-acteyl-11-oxo-beta-boswellic acid
-
-
3-O-acteyl-beta-boswellic acid
-
-
3-oxo-8,24-dienetirucallic acid
-
16.7% residual activity at 0.01 mM
3-[(5E)-3-(4-butylbenzyl)-1-(4-chlorobenzyl)-4-methylidene-5-[(2E)-4-methylpent-2-en-1-ylidene]-4,5-dihydro-1H-pyrrol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00029 mM
3-[1-(4-carbamoylbenzyl)-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl]propanoic acid
-
28% inhibition at 0.001 mM
3-[1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-4-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00025 mM
3-[1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0032 mM
3-[1-(4-chlorobenzyl)-3-methyl-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0011 mM
3-[1-(4-chlorobenzyl)-3-methyl-5-phenyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00060 mM
3-[1-(4-chlorobenzyl)-3-methyl-7-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0043 mM
3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid
-
MK-886
3-[1-(4-chlorobenzyl)-4-(2'-chloro-2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2,2'-difluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2-chlorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2-fluoro-2'-methoxybiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2-fluoro-2'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl]propanoic acid
-
78% inhibition at 0.001 mM
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-phenoxy-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00065 mM
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-phenyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0064 mM
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-[(2-methylphenyl)carbonyl]-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00090 mM
3-[1-(4-chlorobenzyl)-5-(2'-chloro-2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000004 mM
3-[1-(4-chlorobenzyl)-5-(2,2'-difluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000008 mM
3-[1-(4-chlorobenzyl)-5-(2-chlorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000022 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-2'-methoxybiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000005 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-2'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000003 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-3'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000033 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-4'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000031 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-5-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-5-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
3-[1-(4-chlorobenzyl)-5-(3-fluoro-4-pyridin-3-ylphenyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000012 mM
3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0026 mM
3-[1-(4-chlorobenzyl)-5-[2-fluoro-2'-(phenylcarbonyl)biphenyl-4-yl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000006 mM
3-[1-(4-chlorobenzyl)-5-[3-fluoro-4-(pyrimidin-5-ylmethyl)phenyl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000032 mM
3-[1-(p-chlorobenzvl)-5-isopropyl-3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid
-
i.e. 3-[1-(p-chlorobenzvl)-5-isopropyl-3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid or FLAP, formerly designated L-663,536, a lipoxygenase inhibitor, IC50: 0.0016 mM
3-[3-(benzylsulfanyl)-1-(4-chlorobenzyl)-5-[4-[(4-chloro-2-fluorophenyl)ethynyl]phenyl]-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
3-[3-(tert-butylsulfanyl)-1-methyl-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.01 mM
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1-(3-phenylpropyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0032 mM
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1-prop-2-en-1-yl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0067 mM
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.01 mM
3-[3-[(tert-butylsulfanyl)acetyl]-1-(4-chlorobenzyl)-4-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[3-[(tert-butylsulfanyl)acetyl]-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00026 mM
3-[4-(2'-acetyl-2-fluorobiphenyl-4-yl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[4-(4-butoxybenzoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl]propanoic acid
-
32% inhibition at 0.001 mM
3-[4-biphenyl-4-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[4-dodecanoyl-1-(4-hydroxybenzyl)-3,5-dimethyl-1H-pyrrol-2-yl]propanoic acid
-
53% inhibition at 0.001 mM
3-[4-dodecanoyl-1-(4-methoxybenzyl)-3,5-dimethyl-1H-pyrrol-2-yl]propanoic acid
-
72% inhibition at 0.001 mM
3-[4-dodecanoyl-3,5-dimethyl-1-(4-methylbenzyl)-1H-pyrrol-2-yl]propanoic acid
-
52% inhibition at 0.001 mM
3-[4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]propanoic acid
-
83.9% residual activity at 0.01 mM
3-[5-biphenyl-3-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00016 mM
3-[5-biphenyl-4-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000016 mM
3-[5-tert-butyl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00033 mM
3-[6-([1,1'-biphenyl]-4-yl)-1-[(4-chlorophenyl)methyl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
3alpha-acetoxy-7,24-dienetirucallic acid
-
20.6% residual activity at 0.01 mM
3alpha-acetoxy-8,24-dienetirucallic acid
-
36.8% residual activity at 0.01 mM
3alpha-hydroxy-7,24-dienetirucallic acid
-
29.6% residual activity at 0.01 mM
3alpha-hydroxy-8,24-dienetirucallic acid
-
3.5% residual activity at 0.01 mM
3beta-hydroxy-8,24-dienetirucallic acid
-
29.2% residual activity at 0.01 mM
4'-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]biphenyl-4-ol
-
73.6% residual activity at 0.03 mM
4'-[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]biphenyl-3-ol
-
60.1% residual activity at 0.03 mM
4'-[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]biphenyl-4-ol
-
89% residual activity at 0.03 mM
4'-[1-[2-(2-methylphenyl)ethyl]-1H-1,2,3-triazol-4-yl]biphenyl-4-amine
-
98.2% residual activity at 0.03 mM
4,(23)-dihydro-11-oxo-roburic acid
-
21.6% residual activity at 0.01 mM
4,(23)-dihydronyctanthic acid
-
74.1% residual activity at 0.01 mM
4,(23)-dihydroroburic acid
-
92.4% residual activity at 0.01 mM
4-(2'-[[2-chloro-5-(trifluoromethyl)phenoxy]methyl]biphenyl-4-yl)-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
91.9% residual activity at 0.03 mM
4-(2'-[[2-chloro-5-(trifluoromethyl)phenoxy]methyl]biphenyl-4-yl)-1-[2-(2-methylphenyl)ethyl]-1H-1,2,3-triazole
-
87.9% residual activity at 0.03 mM
4-(3-chlorobenzyl)-2,6-bis[4-(trifluoromethoxy)phenyl]-4H-thieno[3,2-b]pyrrole-5-carboxylic acid
-
-
4-(4'-phenoxybiphenyl-4-yl)-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
88.7% residual activity at 0.03 mM
4-(4-benzylphenyl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole
-
-
4-(4-chlorobenzyl)-2,6-bis[4-(trifluoromethoxy)phenyl]-4H-thieno[3,2-b]pyrrole
-
-
4-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)butanoic acid
-
70% inhibition at 0.001 mM
4-(biphenyl-4-yl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole
-
-
4-(phenylethynyl)-N-(2-sulfamoylbenzene-1-sulfonyl)benzamide
AZ-7847
4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzamide
-
-
4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzoic acid
-
-
4-chloro-2-([[(1S,2S)-2-(2,2-dimethylpropanamido)cyclopentyl]methyl]amino)benzoic acid
-
4-chloro-2-([[(1S,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]methyl]amino)benzoic acid
-
4-chloro-2-[([(1S,2S)-2-[(1-phenylpiperidine-4-carbonyl)amino]cyclopentyl]methyl)amino]benzoic acid
-
4-chloro-2-[2-[(1S,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]benzoic acid
-
4-chloro-2-[[(1R,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]methoxy]benzoic acid
-
4-dodecanoyl-1,3,5-trimethyl-1H-pyrrole-2-carboxylic acid
4-dodecanoyl-3,5-dimethyl-1-phenylpyrrole-2-carboxylic acid
-
99% inhibition at 0.001 mM
4-dodecanoyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid
-
62% inhibition at 0.001 mM
4-fluoro-2-[2-[(1S,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]benzoic acid
-
4-methyl-2-[2-[(1S,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]benzoic acid
-
4-[(4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1H-1,2,3-triazol-1-yl)sulfonyl]benzoic acid
-
59.8% residual activity at 0.03 mM
4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
96.8% residual activity at 0.03 mM
4-[4-(phenanthren-9-yl)phenyl]-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
78.2% residual activity at 0.03 mM
4-[4-benzyl-1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-5-yl]benzaldehyde
-
72.1% residual activity at 0.03 mM
4-[[2-(2-carboxyethyl)-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-1-yl]methyl]benzoic acid
-
27% inhibition at 0.001 mM
4-[[4-(biphenyl-4-yl)-1H-1,2,3-triazol-1-yl]methyl]-3-nitrobenzoic acid
-
most efficient inhibitor of mPGES-1, 12% residual activity at 0.03 mM
5-(4-bromophenyl)-3-(2-chloro-6-fluorophenyl)-1,2,4-oxadiazole
-
-
5-(4-cyclohexylphenyl)-1-[4-(1-methylethoxy)benzyl]-1H-indole-2-carboxylic acid
-
-
5-(4-tert-butylphenyl)-1-[4-(1-methylethoxy)benzyl]-1H-indole-2-carboxylic acid
-
-
5-(4-tert-butylphenyl)-3-[4-(1-methylethoxy)phenyl]-1-[4-[(1-methylethyl)amino]benzyl]-1H-indole-2-carboxylic acid
-
-
5-(acetamidomethyl)-2-(difluoromethyl)-N-[4-methyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]pyridine-3-carboxamide
-
-
5-(dimethylamino)-N-[4'-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]biphenyl-4-yl]naphthalene-1-sulfonamide
-
85% residual activity at 0.03 mM
5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)-2-(trifluoromethyl)benzamide
-
-
5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)-2-methylbenzamide
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(1,3-thiazol-2-ylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclohex-1-en-1-ylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclohexylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclopropylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(pyridin-3-ylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-ethynylpyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(2-chlorophenyl)ethynyl]pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(3-chlorophenyl)ethynyl]pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(4-chlorophenyl)ethynyl]pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-5-methyl-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
-
5-[5-(2-chloro-6-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-(phenylethynyl)pyridine
-
-
5-[5-bromo-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
5-[5-chloro-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
-
6-nitro-3-(m-tolylamino) benzo[d]isothiazole 1,1-dioxide
-
i.e. JMC-7
6-nitro-N-phenyl-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
6-nitro-N-[3-(propan-2-yl)phenyl]-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
7-hydroxy-N,N'-bis(2,4,6-trimethylphenyl)naphthalene-1,3-disulfonamide
-
-
aminomethyl 4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzenesulfinate
-
-
cysteinyl leukotriene LTC4
-
-
deoxy-prostaglandin J2
-
IC50: 0.0003 mM
dexamethasone
-
inhibition of cytokine-induced expression of isoform mPGES-1, while isoforms mPGES-2 and cPGES remain unaffected
eicosapentaenoic acid
-
-
ethyl 2-([4-[3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propoxy]phenyl]sulfanyl)hexanoate
-
-
ethyl 2-([4-[3-(biphenyl-4-yloxy)propoxy]phenyl]sulfanyl)hexanoate
-
-
ethyl 2-([4-[3-(quinolin-6-yloxy)propoxy]phenyl]sulfanyl)hexanoate
-
83.9% residual activity at 0.01 mM
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]nonanoate
-
-
lupeolic acid
-
43.1% residual activity at 0.01 mM
methyl 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoate
-
IC50: 0.0072 mM
methyl 4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzenesulfinate
-
-
methyl 4-[6-bromo-2-(2-chloro-6-fluorophenyl)-1H-phenanthro[9,10-d]imidazol-9-yl]but-3-ynoate
-
-
MK-0886
0.002 mM, 50% inhibition
N-(1,3-benzodioxol-4-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(2-methylphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(2-[2-chloro-5-[(2-methylpropanamido)methyl]phenyl]-4-oxo-3,4-dihydroquinazolin-7-yl)cyclopropanecarboxamide
74% inhibition at 0.01 mM
N-(3',4'-dichloro[1,1'-biphenyl]-4-yl)-4-hydroxy-1,1-dioxo-1,2-dihydro-1lambda~6~,2-benzothiazine-3-carboxamide
N-(3,4-dimethoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-bromobenzyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-bromophenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-chloro-2-methylphenyl)-6-[2-chloro-6-(trifluoromethyl)benzamido]-2-(methoxymethyl)-1H-benzimidazole-4-carboxamide
-
N-(3-chlorophenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-methoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-tert-butylphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(4-bromophenyl)-2-[2-chloro-5-[(2,2-dimethylpropanamido)methyl]anilino]-6-(2,2-difluoroethoxy)-1-methyl-1H-benzimidazole-5-carboxamide
-
N-(4-chloro-2-fluorophenyl)-2-[2,6-dichloro-3-[(2,2-dimethylpropanamido)methyl]anilino]-6-(2,2-difluoroethoxy)-1-methyl-1H-benzimidazole-5-carboxamide
-
N-(4-methoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(5-bromonaphthalen-1-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(6-nitro-1,1-dioxido-1,2-benzothiazol-3-yl)quinolin-5-amine
-
-
N-(biphenyl-3-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(cyclohexylmethyl)-2-[(3,5-dichloropyridin-4-yl)amino]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
N-(cyclohexylmethyl)-2-[(3,5-dichloropyridin-4-yl)amino]-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
N-(cyclopentylmethyl)-2-(2,6-dichloroanilino)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
N-(cyclopropylmethyl)-2-(2,6-dichloroanilino)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
N-(cyclopropylmethyl)-2-[(3,5-dichloropyridin-4-yl)amino]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
N-([3-[(4-chlorophenyl)ethynyl]phenyl]methyl)-N'-propan-2-yl-N-([3-[(pyridin-4-yl)ethynyl]phenyl]methyl)urea
-
N-([4-chloro-3-[4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazolin-2-yl]phenyl]methyl)-2-methylpropanamide
-
N-([4-chloro-3-[7-chloro-4-oxo-6-(3-oxopiperazin-1-yl)-3,4-dihydroquinazolin-2-yl]phenyl]methyl)-2-methylpropanamide
79% inhibition at 0.01 mM
N-([4-chloro-3-[7-chloro-4-oxo-6-(pyridin-4-yl)-3,4-dihydroquinazolin-2-yl]phenyl]methyl)-2-methylpropanamide
-
N-([4-chloro-3-[7-chloro-6-(4-hydroxypiperidin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]phenyl]methyl)-2-methylpropanamide
-
N-([4-chloro-3-[7-chloro-6-(4-methylpiperazin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]phenyl]methyl)-2-methylpropanamide
75% inhibition at 0.01 mM
N-([4-chloro-3-[7-chloro-6-(morpholin-4-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]phenyl]methyl)-2-methylpropanamide
-
N-cyclohexyl-2-(2,6-dichloroanilino)-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
N-cyclohexyl-2-[(3,5-dichloropyridin-4-yl)amino]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
N-cyclohexyl-2-[(3,5-dichloropyridin-4-yl)amino]-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
-
N-cyclopentyl-1-[5,6-diamino-1-(3-amino-4-fluorophenyl)-1H-benzimidazol-2-yl]piperidine-4-carboxamide
-
-
N-tert-butyl-1-(7-chloro-2-[2-chloro-5-[(2-methylpropanamido)methyl]phenyl]-4-oxo-3,4-dihydroquinazolin-6-yl)azetidine-3-carboxamide
-
N-[(4-chloro-3-[4-oxo-6-[4-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
-
N-[(4-chloro-3-[4-oxo-7-[4-(trifluoromethyl)phenyl]-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl]phenyl)methyl]-2-methylpropanamide
-
N-[(4-chloro-3-[4-oxo-7-[4-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
-
N-[(4-chloro-3-[4-oxo-7-[4-(trifluoromethyl)piperidin-1-yl]-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
-
N-[(4-chloro-3-[4-oxo-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
-
N-[(4-chloro-3-[7-chloro-4-oxo-6-[4-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
-
N-[(4-chloro-3-[7-chloro-6-[(3R)-3-hydroxypyrrolidin-1-yl]-4-oxo-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
95% inhibition at 0.01 mM
N-[(4-chloro-3-[7-chloro-6-[(3S)-3-hydroxypyrrolidin-1-yl]-4-oxo-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
91% inhibition at 0.01 mM
N-[(4-chloro-3-[7-chloro-6-[4-(difluoromethyl)piperidin-1-yl]-4-oxo-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
-
N-[(6-chloro-5-[4-oxo-7-[4-(trifluoromethyl)phenyl]-3,4-dihydropyrido[4,3-d]pyrimidin-2-yl]pyridin-3-yl)methyl]-2-methylpropanamide
-
N-[3-(4-bromophenyl)-4-oxo-3,4-dihydrophthalazin-6-yl]-2-chloro-6-fluorobenzamide
-
N-[3-[(4-bromophenyl)carbamoyl]-4-(2,2-difluoroethoxy)phenyl]-2-chloro-5-[(2,2-dimethylpropanamido)methyl]benzamide
-
N-[4-chloro-3-(5-methyl-1,3-benzoxazol-2-yl)phenyl]-2-(trifluoromethyl)benzamide
-
-
N-[5-(4-chlorophenyl)-1H-imidazol-2-yl]-2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]benzamide
-
-
N-[5-(4-chlorophenyl)-1H-imidazol-2-yl]-2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]pyridine-3-carboxamide
-
-
N-[5-(4-chlorophenyl)-4-methyl-1H-imidazol-2-yl]-2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]pyridine-3-carboxamide
-
-
N-[[3-(7-amino-4-oxo-3,4-dihydroquinazolin-2-yl)-4-chlorophenyl]methyl]-2-methylpropanamide
70% inhibition at 0.01 mM
N-[[3-(7-bromo-4-oxo-3,4-dihydroquinazolin-2-yl)-4-chlorophenyl]methyl]-2-methylpropanamide
-
N-[[4-chloro-3-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methyl]-2-methylpropanamide
67% inhibition at 0.01 mM
N-[[4-chloro-3-(7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methyl]-2-methylpropanamide
-
N-[[4-chloro-3-(7-chloro-6-cyclopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methyl]-2-methylpropanamide
-
N-[[4-chloro-3-(7-chloro-6-methoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methyl]-2-methylpropanamide
-
N-[[4-chloro-3-(7-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methyl]-2-methylpropanamide
98% inhibition at 0.01 mM
N-[[4-chloro-3-(7-methoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methyl]-2-methylpropanamide
-
N-[[4-chloro-3-(7-nitro-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methyl]-2-methylpropanamide
-
N-[[6-(difluoromethyl)-5-[4-oxo-7-[4-(trifluoromethyl)phenyl]-3,4-dihydropyrido[4,3-d]pyrimidin-2-yl]pyridin-3-yl]methyl]-2-methylpropanamide
-
N-[[6-(difluoromethyl)-5-[4-oxo-7-[4-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-2-yl]pyridin-3-yl]methyl]-2-methylpropanamide
-
roburic acid
-
83.9% residual activity at 0.01 mM
sodium 3-[1-[(4-chlorophenyl)methyl]-5-(2-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoate
-
-
YS121
-
reversible and noncompetitive inhibition
[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]methyl benzoate
-
76.1% residual activity at 0.03 mM
[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl](phenyl)acetic acid
-
-
[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]acetic acid
-
66.4% residual activity at 0.01 mM
1-[5-chloro-6-(4-chlorophenyl)-1,3-benzoxazol-2-yl]-N-[(1S,3S)-3-(hydroxymethyl)cyclohexyl]piperidine-4-carboxamide
-
1-[5-chloro-6-(4-chlorophenyl)-1,3-benzoxazol-2-yl]-N-[(1S,3S)-3-(hydroxymethyl)cyclohexyl]piperidine-4-carboxamide
PF-4693627
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)benzene-1,3-dicarbonitrile
-
-
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)benzene-1,3-dicarbonitrile
-
fludrocortisone
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)benzene-1,3-dicarbonitrile
MF-63
2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]-N-[4-methyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]pyridine-3-carboxamide
-
-
2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]-N-[4-methyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]pyridine-3-carboxamide
-
2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]-N-[5-methyl-4-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]pyridine-3-carboxamide
-
-
2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]-N-[5-methyl-4-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]pyridine-3-carboxamide
-
2-chloro-5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)benzamide
-
-
2-chloro-5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)benzamide
-
3-(4-dodecanoyl-1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)propanoic acid
-
-
3-(4-dodecanoyl-1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)propanoic acid
-
90% inhibition at 0.001 mM
3-[1-(4-chlorobenzyl)-5-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-5-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000007 mM
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
75% inhibition at 0.01 mM
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
12% residual activity at 0.03 mM
4-dodecanoyl-1,3,5-trimethyl-1H-pyrrole-2-carboxylic acid
-
37% inhibition at 0.001 mM
4-dodecanoyl-1,3,5-trimethyl-1H-pyrrole-2-carboxylic acid
-
59% inhibition at 0.001 mM
5-[5-bromo-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
-
5-[5-bromo-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
AF3442
-
-
MF63
-
-
MF63
i.e. 2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile
MK-886
-
-
MK-886
-
inhibition of cytokine-induced expression of isoform mPGES-1, while isoforms mPGES-2 and cPGES remain unaffected
MK-886
-
i.e. 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid
N-(3',4'-dichloro[1,1'-biphenyl]-4-yl)-4-hydroxy-1,1-dioxo-1,2-dihydro-1lambda~6~,2-benzothiazine-3-carboxamide
-
N-(3',4'-dichloro[1,1'-biphenyl]-4-yl)-4-hydroxy-1,1-dioxo-1,2-dihydro-1lambda~6~,2-benzothiazine-3-carboxamide
PF-1984
NS-398
-
-
NS-398
-
COX-2 inhibitor, IC50: 0.01-0.02 mM
PF-9184
-
PF-9184
-
potent, competitive and reversible mPGES-1 inhibitor, i.e. N-(3',4'-dichlorobiphenyl-4-yl)-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
additional information
-
glucocorticosteroids, down-regulation of the enzyme
-
additional information
-
structure-activity relationship analysis of inhibitors
-
additional information
-
not inhibited by BWA4C, i.e. (E)-N-hydroxy-N-(3-(3-phenoxyphenyl)-allyl)acetamide
-
additional information
-
pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1, overview. No inhibition at 0.001 mM by 3-(4-butanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid, 3-(4-heptanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid, 3-(1,3,5-trimethyl-4-octanoyl-1H-pyrrol-2-yl)propanoic acid, 3-(4-decanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid, 3-[1,3,5-trimethyl-4-[2-(octyloxy)benzoyl]-1H-pyrrol-2-yl]propanoic acid, 3-[4-(3-heptyloxybenzoyl)-1,3,5-trimethylpyrrol-2-yl]propionic acid, 3-(4-benzoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid, 3-[1,3,5-trimethyl-4-(naphthalen-1-ylcarbonyl)-1H-pyrrol-2-yl]propanoic acid, 3-[1,3,5-trimethyl-4-(naphthalen-2-ylcarbonyl)-1H-pyrrol-2-yl]propanoic acid, 3-[4-(2-ethylbenzoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl]propanoic acid, 3-[4-(4-ethylbenzoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl]propanoic acid, 3-[4-(4-benzylbenzoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl]propanoic acid, 4-dodecanoyl-1-methyl-1H-pyrrole-2-carboxylic acid, (4-dodecanoyl-1-methyl-1H-pyrrol-2-yl)acetic acid, and 3-(4-dodecanoyl-1-methyl-1H-pyrrol-2-yl)propanoic acid
-
additional information
-
synthesis and inhibitory potency of a series of 6-nitro-3-(m-tolylamino) benzo[d]isothiazole 1,1-dioxide analogues against microsomal prostaglandin E2 synthase. No inhibition by Zileuton
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Aberrant Crypt Foci
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis.
Aberrant Crypt Foci
Genetic-deletion of Cyclooxygenase-2 Downstream Prostacyclin Synthase Suppresses Inflammatory Reactions but Facilitates Carcinogenesis, unlike Deletion of Microsomal Prostaglandin E Synthase-1.
Aberrant Crypt Foci
Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis.
Acute Kidney Injury
Aggravation of acute kidney injury by mPGES-2 down regulation is associated with autophagy inhibition and enhanced apoptosis.
Acute Kidney Injury
Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis.
Acute Kidney Injury
Author Correction: Aggravation of acute kidney injury by mPGES-2 down regulation is associated with autophagy inhibition and enhanced apoptosis.
Acute Lung Injury
Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice.
Adenocarcinoma
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue.
Adenocarcinoma
Clinical significance of prostaglandin E synthase expression in gastric cancer tissue.
Adenocarcinoma
Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors.
Adenocarcinoma
Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine.
Adenocarcinoma
Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines.
Adenocarcinoma
Expression of prostaglandin E synthase in Barrett's cancer.
Adenocarcinoma
Hypoxia and prostaglandin E receptor 4 signalling pathways synergise to promote endometrial adenocarcinoma cell proliferation and tumour growth.
Adenocarcinoma
Inhibition of GSH-dependent PGH2 isomerase in mammary adenocarcinoma cells by allicin.
Adenocarcinoma
Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production.
Adenocarcinoma
NADPH Oxidase NOX5-S and NF-?B1 Mediate Acid-Induced Microsomal Prostaglandin Synthase-1 (Mpges1) Expression in Barrett's Esophageal Adenocarcinoma (EA) Cells.
Adenocarcinoma
Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis.
Adenoma
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue.
Adenoma
COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours.
Adenoma
Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression.
Adenoma
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis.
Adenoma
Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma.
Adenoma
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer.
Adenomatous Polyposis Coli
Association between adenomatosis polyposis coli functional status and microsomal prostaglandin E synthase-1 expression in colorectal cancer.
Adenomatous Polyposis Coli
Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis.
Adenomatous Polyposis Coli
Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials.
Albuminuria
mPGES-1-derived PGE2 contributes to adriamycin-induced podocyte injury.
Alveolar Bone Loss
Membrane-bound prostaglandin E synthase-1-mediated prostaglandin E2 production by osteoblast plays a critical role in lipopolysaccharide-induced bone loss associated with inflammation.
Alzheimer Disease
Cytosolic prostaglandin E synthase: expression patterns in control and Alzheimer's disease brains.
Alzheimer Disease
Elevated microsomal prostaglandin-E synthase-1 in Alzheimer's disease.
Alzheimer Disease
Microsomal prostaglandin E synthase-1 is induced in alzheimer's disease and its deletion mitigates alzheimer's disease-like pathology in a mouse model.
Alzheimer Disease
Microsomal prostaglandin E synthase-2: Cellular distribution and expression in Alzheimer's disease.
Alzheimer Disease
The Role of mPGES-1 in Inflammatory Brain Diseases.
Alzheimer Disease
[Trends in nonsteroidal anti-inflammatory drug development and application]
Amyotrophic Lateral Sclerosis
Expression of microsomal prostaglandin e synthase-1 in the spinal cord in a transgenic mouse model of amyotrophic lateral sclerosis.
Anemia
Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model.
Anemia
Microsomal prostaglandin E synthase 1 deletion retards renal disease progression but exacerbates anemia in mice with renal mass reduction.
Aneurysm
Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation.
Aneurysm
Paradoxical Increase in Mortality and Rupture of Intracranial Aneurysms in Microsomal Prostaglandin E2 Synthase Type 1-Deficient Mice: Attenuation by Aspirin.
Aortic Aneurysm
A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine aortic aneurysm model.
Aortic Aneurysm
Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease.
Aortic Aneurysm
Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury.
Aortic Aneurysm, Abdominal
Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation.
Apnea
Comparison of cardiorespiratory and EEG abnormalities with seizures in adults and children.
Apnea
mPGES-1 and Prostaglandin E(2:) vital role in inflammation, hypoxic response, and survival.
Apnea
Near SUDEP during bilateral stereo-EEG monitoring characterized by diffuse postictal EEG suppression.
Apnea
The induced prostaglandin E2 pathway is a key regulator of the respiratory response to infection and hypoxia in neonates.
Arthralgia
Identification and Characterization of Novel Microsomal Prostaglandin E Synthase-1 Inhibitors for Analgesia.
Arthritis
A novel mPGES-1 inhibitor alleviates inflammatory responses by downregulating PGE2 in experimental models.
Arthritis
Anti-inflammatory properties of prostaglandin E2: Deletion of microsomal prostaglandin E synthase-1 exacerbates non-immune inflammatory arthritis in mice.
Arthritis
Aurothiomalate inhibits the expression of mPGES-1 in primary human chondrocytes.
Arthritis
Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis.
Arthritis
Defective generation of a humoral immune response is associated with a reduced incidence and severity of collagen-induced arthritis in microsomal prostaglandin E synthase-1 null mice.
Arthritis
Effects of antirheumatic treatments on the prostaglandin E2 biosynthetic pathway.
Arthritis
IL-1?/HMGB1 complexes promote the PGE2 biosynthesis pathway in synovial fibroblasts.
Arthritis
Induction of microsomal prostaglandin E synthase in the rat brain endothelium and parenchyma in adjuvant-induced arthritis.
Arthritis
Inhibition of Matrix Metalloproteinase-3 and -13 Synthesis Induced by IL-1{beta} in Chondrocytes from Mice Lacking Microsomal Prostaglandin E Synthase-1.
Arthritis
Liver X receptor ligands inhibit the lipopolysaccharide-induced expression of microsomal prostaglandin E synthase-1 and diminish prostaglandin E2 production in murine peritoneal macrophages.
Arthritis
Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model.
Arthritis
Microsomal prostaglandin E synthase-1, ephrins, and ephrin kinases as suspected therapeutic targets in arthritis: exposed by "criminal profiling".
Arthritis
Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2.
Arthritis
mPGES-1 as a novel target for arthritis.
Arthritis
mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis.
Arthritis
Potential roles of microsomal prostaglandin E synthase-1 in rheumatoid arthritis.
Arthritis
Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis.
Arthritis
Prostaglandin E synthase in the pathophysiology of arthritis.
Arthritis
Regulation of gene expression by MF63, a selective inhibitor of microsomal PGE synthase 1 (mPGES1) in human osteoarthritic chondrocytes.
Arthritis
Suppressing mPGES-1 expression by sinomenine ameliorates inflammation and arthritis.
Arthritis
Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways.
Arthritis
Variants of gene for microsomal prostaglandin E2 synthase show association with disease and severe inflammation in rheumatoid arthritis.
Arthritis, Experimental
Anti-inflammatory and analgesic activity of a novel inhibitor of microsomal prostaglandin E synthase-1 expression.
Arthritis, Experimental
Anti-inflammatory properties of prostaglandin E2: Deletion of microsomal prostaglandin E synthase-1 exacerbates non-immune inflammatory arthritis in mice.
Arthritis, Experimental
Defective generation of a humoral immune response is associated with a reduced incidence and severity of collagen-induced arthritis in microsomal prostaglandin E synthase-1 null mice.
Arthritis, Experimental
Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase.
Arthritis, Experimental
Prostaglandin E synthase in the pathophysiology of arthritis.
Arthritis, Experimental
Reduced T cell-dependent humoral immune response in microsomal prostaglandin E synthase-1 null mice is mediated by nonhematopoietic cells.
Arthritis, Rheumatoid
Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells.
Arthritis, Rheumatoid
Defective generation of a humoral immune response is associated with a reduced incidence and severity of collagen-induced arthritis in microsomal prostaglandin E synthase-1 null mice.
Arthritis, Rheumatoid
Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.
Arthritis, Rheumatoid
Effects of antirheumatic treatments on the prostaglandin E2 biosynthetic pathway.
Arthritis, Rheumatoid
Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium.
Arthritis, Rheumatoid
Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase.
Arthritis, Rheumatoid
Lead Discovery for Microsomal Prostaglandin E Synthase Using a Combination of High-Throughput Fluorescent-Based Assays and RapidFire Mass Spectrometry.
Arthritis, Rheumatoid
Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells.
Arthritis, Rheumatoid
Microsomal prostaglandin e synthase-1 in rheumatic diseases.
Arthritis, Rheumatoid
mPGES-1 deletion affects platelet functions in mice.
Arthritis, Rheumatoid
Murine mPGES-1 3D structure elucidation and inhibitors binding mode predictions by homology modeling and site-directed mutagenesis.
Arthritis, Rheumatoid
Potential roles of microsomal prostaglandin E synthase-1 in rheumatoid arthritis.
Arthritis, Rheumatoid
Prostaglandin E synthase in the pathophysiology of arthritis.
Arthritis, Rheumatoid
Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts.
Arthritis, Rheumatoid
Structural basis for induced formation of the inflammatory mediator prostaglandin E2.
Arthritis, Rheumatoid
Suppressing mPGES-1 expression by sinomenine ameliorates inflammation and arthritis.
Arthritis, Rheumatoid
Variants of gene for microsomal prostaglandin E2 synthase show association with disease and severe inflammation in rheumatoid arthritis.
Asthma
A low dose of Mycoplasma pneumoniae infection enhances an established allergic inflammation in mice: the role of the prostaglandin E pathway.
Asthma
Common household chemicals and the allergy risks in pre-school age children.
Asthma
Identification of Four Novel Loci in Asthma in European and African American Populations.
Asthma
Physiology and pharmacology of prostaglandins.
Asthma
Selective downregulation of prostaglandin E2-related pathways by the Th2 cytokine IL-13.
Asthma
Sources of propylene glycol and glycol ethers in air at home.
Astrocytoma
Interleukin-8 (IL-8) overexpression in astrocytomas is induced by prostaglandin E2 (PGE2) and is associated to the transcription factors CCAAT enhancer binding protein-beta (C/EBP-?) and C/EBP Homologous Protein (CHOP).
Astrocytoma
Microsomal prostaglandin E synthase-1 regulates human glioma cell growth via prostaglandin E(2)-dependent activation of type II protein kinase A.
Atherosclerosis
An Update of Microsomal Prostaglandin E Synthase-1 and PGE2 Receptors in Cardiovascular Health and Diseases.
Atherosclerosis
Cardiovascular Consequences of Prostanoid I Receptor Deletion in Microsomal Prostaglandin E Synthase-1-Deficient Hyperlipidemic Mice.
Atherosclerosis
Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis.
Atherosclerosis
Inhibitors of the Microsomal Prostaglandin E(2) Synthase-1 as Alternative to Non Steroidal Anti-inflammatory Drugs (NSAIDs) - A Critical Review.
Atherosclerosis
Membrane prostaglandin E synthase-1: a novel therapeutic target.
Atherosclerosis
Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation.
Atherosclerosis
Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease.
Atherosclerosis
Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury.
Atherosclerosis
Molecular docking and competitive binding study discovered different binding modes of microsomal prostaglandin E synthase-1 inhibitors.
Atherosclerosis
Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice.
Atherosclerosis
Myeloid Cell mPges-1 Deletion Attenuates Mortality Without Affecting Remodeling After Acute Myocardial Infarction in Mice.
Atherosclerosis
PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.
Atherosclerosis
Prostaglandin E2 synthesis in pigeon aorta: comparison of atherosclerosis-resistant (Show Racer) and atherosclerosis-prone (White Carneau) breeds.
Atherosclerosis
Sex-dependent compensatory mechanisms preserve blood pressure homeostasis in prostacyclin receptor-deficient mice.
Bacterial Infections
An inflammatory pathway to apnea and autonomic dysregulation.
Bacterial Infections
Increased lethality and defective pulmonary clearance of Streptococcus pneumoniae in microsomal prostaglandin E synthase-1-knockout mice.
Barrett Esophagus
Effect of Proton Pump Inhibitor Therapy on NOX5, mPGES1 and iNOS expression in Barrett's Esophagus.
Bone Diseases
Membrane-bound prostaglandin E synthase-1-mediated prostaglandin E2 production by osteoblast plays a critical role in lipopolysaccharide-induced bone loss associated with inflammation.
Bone Neoplasms
Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice.
Bone Resorption
Aminothiazoles inhibit osteoclastogenesis and PGE2 production in LPS-stimulated co-cultures of periodontal ligament and RAW 264.7 cells, and RANKL-mediated osteoclastogenesis and bone resorption in PBMCs.
Bone Resorption
Capsaicin, a TRPV1 Ligand, Suppresses Bone Resorption by Inhibiting the Prostaglandin E Production of Osteoblasts, and Attenuates the Inflammatory Bone Loss Induced by Lipopolysaccharide.
Bone Resorption
Contribution of membrane-associated prostaglandin E2 synthase to bone resorption.
Bone Resorption
Inhibition of microsomal prostaglandin E synthase-1 by aminothiazoles decreases prostaglandin E2 synthesis in vitro and ameliorates experimental periodontitis in vivo.
Bone Resorption
Membrane-bound prostaglandin E synthase-1-mediated prostaglandin E2 production by osteoblast plays a critical role in lipopolysaccharide-induced bone loss associated with inflammation.
Bone Resorption
Prostaglandin E--a powerful anabolic agent for generalized or site-specific bone formation.
Bradycardia
Comparison of cardiorespiratory and EEG abnormalities with seizures in adults and children.
Brain Concussion
AH6809 decreases production of inflammatory mediators by PGE2 - EP2 - cAMP signaling pathway in an experimentally induced pure cerebral concussion in rats.
Brain Diseases
Postictal stertor: Associations with focal and bilateral seizure types.
Brain Diseases
The Role of mPGES-1 in Inflammatory Brain Diseases.
Brain Injuries
AH6809 decreases production of inflammatory mediators by PGE2 - EP2 - cAMP signaling pathway in an experimentally induced pure cerebral concussion in rats.
Brain Injuries
Intracerebral hemorrhage outcomes following selective blockade or stimulation of the PGE2 EP1 receptor.
Brain Ischemia
Prostaglandin E receptors as targets for ischemic stroke: Novel evidence and molecular mechanisms of efficacy.
Brain Ischemia
The role of prostaglandin e2 in stroke-reperfusion injury.
Brain Neoplasms
Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme.
Brain Neoplasms
Interleukin-8 (IL-8) overexpression in astrocytomas is induced by prostaglandin E2 (PGE2) and is associated to the transcription factors CCAAT enhancer binding protein-beta (C/EBP-?) and C/EBP Homologous Protein (CHOP).
Brain Neoplasms
Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets.
Breast Diseases
Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy.
Breast Neoplasms
Cigarette Smoke Regulates Calcium-Independent Phospholipase A2 Metabolic Pathways in Breast Cancer.
Breast Neoplasms
Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival.
Breast Neoplasms
Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis.
Breast Neoplasms
Kruppel-like Factor 5 Transcription Factor Promotes Microsomal Prostaglandin E2 Synthase 1 Gene Transcription in Breast Cancer.
Breast Neoplasms
Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy.
Breast Neoplasms
MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer.
Breast Neoplasms
Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines.
Candidiasis
C. albicans activates cyclooxygenase but not its product prostaglandin E? in HPV 16-stabilized cells.
Carcinogenesis
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue.
Carcinogenesis
COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours.
Carcinogenesis
Elevated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in primary sclerosing cholangitis: ?mplications for cholangiocarcinogenesis.
Carcinogenesis
Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis.
Carcinogenesis
Expression of microsomal prostaglandin E2 synthase-1 and its role in human hepatocellular carcinoma.
Carcinogenesis
Expression of prostaglandin E synthase in Barrett's cancer.
Carcinogenesis
Gene Deletion of Microsomal Prostaglandin E Synthase-1 Suppresses Chemically Induced Skin Carcinogenesis.
Carcinogenesis
Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines.
Carcinogenesis
Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis.
Carcinogenesis
Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice.
Carcinogenesis
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis.
Carcinogenesis
Genetic-deletion of Cyclooxygenase-2 Downstream Prostacyclin Synthase Suppresses Inflammatory Reactions but Facilitates Carcinogenesis, unlike Deletion of Microsomal Prostaglandin E Synthase-1.
Carcinogenesis
Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice.
Carcinogenesis
Hypoxia and prostaglandin E receptor 4 signalling pathways synergise to promote endometrial adenocarcinoma cell proliferation and tumour growth.
Carcinogenesis
Identification of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol.
Carcinogenesis
Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers.
Carcinogenesis
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Carcinogenesis
Inhibitors of the Microsomal Prostaglandin E(2) Synthase-1 as Alternative to Non Steroidal Anti-inflammatory Drugs (NSAIDs) - A Critical Review.
Carcinogenesis
Interleukin-8 (IL-8) overexpression in astrocytomas is induced by prostaglandin E2 (PGE2) and is associated to the transcription factors CCAAT enhancer binding protein-beta (C/EBP-?) and C/EBP Homologous Protein (CHOP).
Carcinogenesis
Membrane prostaglandin E synthase-1: a novel therapeutic target.
Carcinogenesis
Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis.
Carcinogenesis
Microsomal Prostaglandin E Synthase-1 Inhibits PTEN and Promotes Experimental Cholangiocarcinogenesis and Tumor Progression.
Carcinogenesis
Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis.
Carcinogenesis
Microsomal Prostaglandin E2 Synthase-1 as a New Macromolecular Drug Target in the Prevention of ?nflammation and Cancer.
Carcinogenesis
Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation-associated colon carcinogenesis.
Carcinogenesis
Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis.
Carcinogenesis
Prostaglandin synthases influence thyroid follicular cell proliferation but not carcinogenesis in rats initiated with N-bis(2-hydroxypropyl)nitrosamine.
Carcinogenesis
Regulation of cyclooxygenase-2 pathway by HER2 receptor.
Carcinogenesis
Role of microsomal prostaglandin E synthase-1 (mPGES-1)-derived prostaglandin E2 in colon carcinogenesis.
Carcinogenesis
Roles of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression and beta-catenin activation in gastric carcinogenesis in N-methyl-N-nitrosourea-treated K19-C2mE transgenic mice.
Carcinogenesis
Targeted over-expression of mPGES-1 and elevated PGE2 production is not sufficient for lung tumorigenesis in mice.
Carcinogenesis
Toward the discovery of new agents able to inhibit the expression of microsomal prostaglandin E synthase-1 enzyme as promising tools in drug development.
Carcinogenesis
[Role of mPGES-1 in the occurrence, progression, metastasis and invasion of hepatocellular carcinoma].
Carcinoma
COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours.
Carcinoma
Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer.
Carcinoma
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis.
Carcinoma
Dioscorea japonica extract down-regulates prostaglandin E2 synthetic pathway and induces apoptosis in lung cancer cells.
Carcinoma
Ellagitannins from Punica granatum leaves suppress microsomal prostaglandin E synthase-1 expression and induce lung cancer cells to undergo apoptosis.
Carcinoma
Expression of COX-1, COX-2 and mPGES-1 in penile and preputial papillomas and squamous cell carcinomas in the horse.
Carcinoma
Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma.
Carcinoma
Expression of microsomal prostaglandin E synthase-1 in human hepatocelluar carcinoma.
Carcinoma
Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines.
Carcinoma
Immunohistochemical Demonstration of Membrane-bound Prostaglandin E(2) Synthase-1 in Papillary Thyroid Carcinoma.
Carcinoma
Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma.
Carcinoma
Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis.
Carcinoma
Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma.
Carcinoma
miR-708-5p targets oncogenic prostaglandin E2 production to suppress a pro-tumorigenic phenotype in lung cancer cells.
Carcinoma
Prostaglandin E synthase is upregulated by Gas6 during cancer-induced venous thrombosis.
Carcinoma
Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression.
Carcinoma
Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx.
Carcinoma
The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis.
Carcinoma
Tumor cells induce COX-2 and mPGES-1 expression in microvascular endothelial cells mainly by means of IL-1 receptor activation.
Carcinoma in Situ
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis.
Carcinoma, Hepatocellular
15d-PGJ? decreases PGE? synthesis in HBx-positive liver cells by interfering EGR1 binding to mPGES-1 promoter.
Carcinoma, Hepatocellular
Expression of microsomal prostaglandin E synthase-1 in human hepatocelluar carcinoma.
Carcinoma, Hepatocellular
Expression of microsomal prostaglandin E2 synthase-1 and its role in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/?-catenin signaling axis.
Carcinoma, Hepatocellular
mPGES-1 expression in non-cancerous liver tissue impacts on postoperative recurrence of HCC.
Carcinoma, Hepatocellular
Proteomic Profile of Reversible Protein Oxidation Using PROP, Purification of Reversibly Oxidized Proteins.
Carcinoma, Lewis Lung
Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis.
Carcinoma, Non-Small-Cell Lung
Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model.
Carcinoma, Non-Small-Cell Lung
Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.
Carcinoma, Non-Small-Cell Lung
Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Dioscorea japonica extract down-regulates prostaglandin E2 synthetic pathway and induces apoptosis in lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Ellagitannins from Punica granatum leaves suppress microsomal prostaglandin E synthase-1 expression and induce lung cancer cells to undergo apoptosis.
Carcinoma, Non-Small-Cell Lung
Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells.
Carcinoma, Non-Small-Cell Lung
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction.
Carcinoma, Non-Small-Cell Lung
mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
Carcinoma, Ovarian Epithelial
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression.
Carcinoma, Squamous Cell
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis.
Carcinoma, Squamous Cell
Expression of COX-1, COX-2 and mPGES-1 in penile and preputial papillomas and squamous cell carcinomas in the horse.
Carcinoma, Squamous Cell
Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
miR-708-5p targets oncogenic prostaglandin E2 production to suppress a pro-tumorigenic phenotype in lung cancer cells.
Carcinoma, Squamous Cell
Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx.
Cardiomegaly
Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion.
Cardiomyopathies
Microsomal Prostaglandin E2 Synthase-1 Deletion Attenuates Isoproterenol-Induced Myocardial Fibrosis in Mice.
Cardiovascular Diseases
Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: role in atherosclerosis.
Cardiovascular Diseases
Microsomal Prostaglandin E Synthase-1 Expression by Aortic Smooth Muscle Cells Attenuates the Differentiated Phenotype.
Cardiovascular Diseases
Microsomal Prostaglandin E2 Synthase-1 Deletion Attenuates Isoproterenol-Induced Myocardial Fibrosis in Mice.
Cardiovascular Diseases
Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice.
Cardiovascular Diseases
PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.
Cardiovascular Diseases
[Research advances of prostaglandin E2 synthases and receptors in cardiovascular diseases].
Carotid Artery Diseases
Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB.
Carotid Stenosis
Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB.
Cerebral Cortical Thinning
Cortical thinning in epilepsy patients with postictal generalized electroencephalography suppression.
Cerebral Hemorrhage
A Promoter polymorphism (rs17222919, -1316T/G) of ALOX5AP is associated with intracerebral hemorrhage in Korean population.
Cerebral Infarction
Pharmacological and genetic analysis of mechanisms underlying detrusor overactivity in rats.
Chemical and Drug Induced Liver Injury
Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury.
Cholangiocarcinoma
Microsomal Prostaglandin E Synthase-1 Inhibits PTEN and Promotes Experimental Cholangiocarcinogenesis and Tumor Progression.
Cholangitis, Sclerosing
Elevated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in primary sclerosing cholangitis: ?mplications for cholangiocarcinogenesis.
Chorioamnionitis
Differential expression and regulation of microsomal prostaglandin E(2) synthase in human fetal membranes and placenta with infection and in cultured trophoblast cells.
Coinfection
c-Jun N-terminal kinase-mediated stabilization of microsomal prostaglandin E2 synthase-1 mRNA regulates delayed microsomal prostaglandin E2 synthase-1 expression and prostaglandin E2 biosynthesis by cardiomyocytes.
Colitis
Apigenin supplementation protects the development of dextran sulfate sodium-induced murine experimental colitis by inhibiting canonical and non-canonical inflammasome signaling pathways.
Colitis
mPGES-1-Mediated Production of PGE2 and EP4 Receptor Sensing Regulate T Cell Colonic Inflammation.
Colitis
Resolution of Cox mediated inflammation by Se supplementation in mouse experimental model of colitis.
Colonic Neoplasms
15-deoxy-Delta12,14-prostaglandin J2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells.
Colonic Neoplasms
Association between adenomatosis polyposis coli functional status and microsomal prostaglandin E synthase-1 expression in colorectal cancer.
Colonic Neoplasms
Garcinol exhibits anti-proliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells.
Colonic Neoplasms
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis.
Colonic Neoplasms
GPx2 counteracts PGE2 production by dampening COX-2 and mPGES-1 expression in human colon cancer cells.
Colonic Neoplasms
Inhibition of microsomal prostaglandin E synthase-1 as targeted therapy in cancer treatment.
Colonic Neoplasms
Methanolic extract of Boswellia serrata exhibits anti-cancer activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells.
Colonic Neoplasms
Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis.
Colonic Neoplasms
Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression.
Colonic Neoplasms
Sulforaphane, a Chemopreventive Compound, Inhibits Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Expression in Human HT-29 Colon Cancer Cells.
Colonic Neoplasms
Upregulation of Prostaglandin E2 by Inducible Microsomal Prostaglandin E Synthase-1 in Colon Cancer.
Colorectal Neoplasms
15-deoxy-Delta12,14-prostaglandin J2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells.
Colorectal Neoplasms
Association between adenomatosis polyposis coli functional status and microsomal prostaglandin E synthase-1 expression in colorectal cancer.
Colorectal Neoplasms
Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2.
Colorectal Neoplasms
Clinical significance of prostaglandin e synthase expression in colorectal cancer.
Colorectal Neoplasms
Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice.
Colorectal Neoplasms
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Colorectal Neoplasms
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer.
Colorectal Neoplasms
Instability of a dinucleotide repeat in the 3'-untranslated region (UTR) of the microsomal prostaglandin E synthase-1 (mPGES-1) gene in microsatellite instability-high (MSI-H) colorectal carcinoma.
Colorectal Neoplasms
Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients.
Colorectal Neoplasms
Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis.
Colorectal Neoplasms
Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression.
Colorectal Neoplasms
[Role of prostaglandins in colon cancer]
Colorectal Neoplasms
[Trends in nonsteroidal anti-inflammatory drug development and application]
Coma
Postictal generalized EEG suppression after generalized convulsive seizures: A double-edged sword.
Corneal Injuries
Expression of microsomal prostaglandin e synthase-1 in fibroblasts of rabbit alkali-burned corneas.
Coronary Occlusion
The effects of microsomal prostaglandin E synthase-1 deletion in acute cardiac ischemia in mice.
Coronary Stenosis
Prostaglandin E2 (PGE2) synthesis pathway is involved in coronary artery stenosis and restenosis.
COVID-19
DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.
COVID-19
What about COVID-19 and arachidonic acid pathway?
Cysts
Expression of Angiotensin II Types 1 and 2 Receptors in Endometriotic Lesions.
Dehydration
Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus.
Dehydration
Influence of prostaglandins on vasoconstrictor responses in the hindquarters vascular bed of the cat.
Dehydration
mPGES-1-derived PGE2 mediates dehydration natriuresis.
Dehydration
Prostaglandin-macromolecule interactions. I. Noncovalent binding of prostaglandins A1, E1, F2alpha, and E2 by human and bovine serum albumins.
Demyelinating Diseases
Endothelial Microsomal Prostaglandin E Synthetase-1 Upregulates Vascularity and Endothelial Interleukin-1? in Deteriorative Progression of Experimental Autoimmune Encephalomyelitis.
Demyelinating Diseases
Microsomal prostaglandin E synthase-1 aggravates inflammation and demyelination in a mouse model of multiple sclerosis.
Demyelinating Diseases
Microsomal Prostaglandin E Synthase-1 Facilitates an Intercellular Interaction between CD4? T Cells through IL-1? Autocrine Function in Experimental Autoimmune Encephalomyelitis.
Dermatitis, Contact
Coordinated action of microsomal prostaglandin E synthase-1 and prostacyclin synthase on contact hypersensitivity.
Dermatomyositis
Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis.
Diabetes Insipidus, Neurogenic
Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus.
Diabetes Mellitus
Influence of a type 2 diabetes associated prostaglandin E synthase 2 polymorphism on blood prostaglandin E2 levels.
Diabetes Mellitus
mPGES-2 deletion remarkably enhances liver injury in streptozotocin-treated mice via induction of GLUT2.
Diabetes Mellitus, Type 2
Association of prostaglandin E synthase 2 (PTGES2) Arg298His polymorphism with type 2 diabetes in two German study populations.
Diabetes Mellitus, Type 2
Influence of a type 2 diabetes associated prostaglandin E synthase 2 polymorphism on blood prostaglandin E2 levels.
Diabetic Retinopathy
Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes.
Drug Resistant Epilepsy
An electroclinical case-control study of sudden unexpected death in epilepsy.
Ductus Arteriosus, Patent
Role of microsomal prostaglandin E synthase-1 (mPGES1)-derived PGE2 in patency of the ductus arteriosus in the mouse.
Dyslipidemias
PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.
Dyspareunia
Discovery and optimization of pyridyl-cycloalkyl-carboxylic acids as inhibitors of microsomal prostaglandin E synthase-1 for the treatment of endometriosis.
Eczema
Common household chemicals and the allergy risks in pre-school age children.
Eczema
Sources of propylene glycol and glycol ethers in air at home.
Encephalomalacia
The effect of Se-deficient diet on gene expression of inflammatory cytokines in chicken brain.
Encephalomyelitis
Endothelial Microsomal Prostaglandin E Synthetase-1 Upregulates Vascularity and Endothelial Interleukin-1? in Deteriorative Progression of Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis
Microsomal prostaglandin E synthase-1 aggravates inflammation and demyelination in a mouse model of multiple sclerosis.
Encephalomyelitis
Microsomal Prostaglandin E Synthase-1 Facilitates an Intercellular Interaction between CD4? T Cells through IL-1? Autocrine Function in Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis
Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Endothelial Microsomal Prostaglandin E Synthetase-1 Upregulates Vascularity and Endothelial Interleukin-1? in Deteriorative Progression of Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Microsomal prostaglandin E synthase-1 aggravates inflammation and demyelination in a mouse model of multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Microsomal Prostaglandin E Synthase-1 Facilitates an Intercellular Interaction between CD4? T Cells through IL-1? Autocrine Function in Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis.
Endometriosis
ARID1A, Prostaglandin E2, and Its Receptor as Possible Predictors of Malignant Transformation of the Endometrium in Endometriosis.
Endometriosis
Discovery and optimization of pyridyl-cycloalkyl-carboxylic acids as inhibitors of microsomal prostaglandin E synthase-1 for the treatment of endometriosis.
Endometriosis
Expression of eicosanoid biosynthetic and catabolic enzymes in peritoneal endometriosis.
Endometriosis
Expression of inducible microsomal prostaglandin E synthase in local lesions of endometriosis patients.
Endometriosis
Relationship between Toll-like receptor-4 and mPGES-1 gene expression in local lesions of endometriosis patients.
Endometriosis
Stretch magnitude- and frequency-dependent cyclooxygenase 2 and prostaglandin E2 up-regulation in human endometrial stromal cells: possible implications in endometriosis.
Endometriosis
The inducible prostaglandin E synthase mPGES-1 regulates growth of endometrial tissues and angiogenesis in a mouse implantation model.
Endometritis
Endometrial expression of selected transcripts in postpartum of primiparous Holstein cows with clinical and subclinical endometritis.
Endometritis
Endometrial expression of selected transcripts involved in prostaglandin synthesis in cows with endometritis.
Endometritis
Evidence for Increased Content of PGF2?, PGE2, and 6-keto-PGF1? in Endometrial Tissue Cultures From Heavy Draft Mares in Anestrus With Endometritis.
Epilepsies, Partial
Postictal generalized EEG suppression is linked to seizure-associated respiratory dysfunction but not postictal apnea.
Epilepsy
Association between semiologic, autonomic, and electrographic seizure characteristics in children with generalized tonic-clonic seizures.
Epilepsy
Autonomic dysregulation in children with epilepsy with postictal generalized EEG suppression following generalized convulsive seizures.
Epilepsy
Cortical thinning in epilepsy patients with postictal generalized electroencephalography suppression.
Epilepsy
Detection of Postictal Generalized Electroencephalogram Suppression: Random Forest Approach.
Epilepsy
Nocturnal seizures are associated with more severe hypoxemia and increased risk of postictal generalized EEG suppression.
Epilepsy
Periictal electroclinical characteristics of postictal generalized electroencephalographic suppression after generalized convulsive seizures.
Epilepsy
Postictal generalized EEG suppression after generalized convulsive seizures: A double-edged sword.
Epilepsy
Postictal generalized EEG suppression is not associated with periictal cardiac autonomic instability in people with convulsive seizures.
Epilepsy
Postictal generalized electroencephalographic suppression following electroconvulsive therapy: Temporal characteristics and impact of anesthetic regimen.
Epilepsy
Postictal generalized electroencephalographic suppression is associated with generalized seizures.
Epilepsy
Prevention of sudden unexpected death in epilepsy: current status and future perspectives.
Epilepsy
Proteomics and Transcriptomics of the Hippocampus and Cortex in SUDEP and High-Risk SUDEP Patients.
Epilepsy
The Role of mPGES-1 in Inflammatory Brain Diseases.
Epilepsy
The SUDEP Risk Inventory: Association with postictal generalized EEG suppression.
Epilepsy
Tonic phase of a generalized convulsive seizure is an independent predictor of postictal generalized EEG suppression.
Epilepsy
Two predictors of postictal generalized EEG suppression: Tonic phase duration and postictal immobility period.
Epilepsy
Voltage-based automated detection of postictal generalized electroencephalographic suppression: Algorithm development and validation.
Epilepsy, Temporal Lobe
Postictal generalized EEG suppression after generalized convulsive seizures: A double-edged sword.
Epilepsy, Temporal Lobe
Postictal generalized electroencephalographic suppression is associated with generalized seizures.
Epiretinal Membrane
Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes.
Erythema
Inflammatory responses of the rabbit eye to prostaglandins.
Erythema
Local gene expression changes after UV-irradiation of human skin.
Esophageal Neoplasms
Induction of prostaglandin E synthase by gastroesophageal reflux contents in normal esophageal epithelial cells and esophageal cancer cells.
Gastritis
Expression of proteins related to prostaglandin E2 biosynthesis is increased in human gastric cancer and during gastric carcinogenesis.
Gastritis
Microsomal prostaglandin E synthase (mPGES)-1, mPGES-2 and cytosolic PGES expression in human gastritis and gastric ulcer tissue.
Gastritis
The role of cyclooxygenase in gastric mucosal protection.
Gastroesophageal Reflux
Induction of prostaglandin E synthase by gastroesophageal reflux contents in normal esophageal epithelial cells and esophageal cancer cells.
Gastroesophageal Reflux
Roles of cyclooxygenase 2 and microsomal prostaglandin E synthase 1 in rat acid reflux oesophagitis.
Gingivitis
The effect of age on prostaglandin-synthesizing enzymes in the development of gingivitis.
Glaucoma
The influence of topical non-steroidal anti-inflammatory drugs on the intraocular pressure lowering effect of topical prostaglandin analogues-A systemic review and meta-analysis.
Glioblastoma
Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme.
Glioma
Induction of prostaglandin E2 synthesis and microsomal prostaglandin E synthase-1 expression in murine microglia by glioma-derived soluble factors. Laboratory investigation.
Glioma
Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma through ceRNA effect of miR-194-5p and lncRNA NEAT1.
Glioma
Interleukin-8 (IL-8) overexpression in astrocytomas is induced by prostaglandin E2 (PGE2) and is associated to the transcription factors CCAAT enhancer binding protein-beta (C/EBP-?) and C/EBP Homologous Protein (CHOP).
Glioma
Microsomal prostaglandin E synthase-1 regulates human glioma cell growth via prostaglandin E(2)-dependent activation of type II protein kinase A.
Glioma
The 1,4 benzoquinone-featured 5-lipoxygenase inhibitor RF-Id induces apoptotic death through downregulation of IAPs in human glioblastoma cells.
Glioma
The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES are all overexpressed in human gliomas.
Goiter, Nodular
Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma.
Hamartoma
Simultaneous expression of COX-2 and mPGES-1 in mouse gastrointestinal hamartomas.
Heart Arrest
Postictal generalized EEG suppression and respiratory dysfunction following generalized tonic-clonic seizures in sleep and wakefulness.
Heart Defects, Congenital
Prostaglandins: a possible regulator of muscle tone in the ductus arteriosus.
Helicobacter Infections
Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia caused by tumor necrosis factor-alpha-dependent inflammation in cyclooxygenase-2/microsomal prostaglandin E synthase-1 transgenic mice.
Hepatitis
Expression of microsomal prostaglandin E synthase-1 in human hepatocelluar carcinoma.
Hepatitis B
15d-PGJ? decreases PGE? synthesis in HBx-positive liver cells by interfering EGR1 binding to mPGES-1 promoter.
Hepatitis, Chronic
mPGES-1 expression in non-cancerous liver tissue impacts on postoperative recurrence of HCC.
Hirschsprung Disease
MPGES-1 derived PGE2 inhibits cell migration by regulating ARP2/3 in the pathogenesis of Hirschsprung disease.
Hydronephrosis
A mouse strain less responsive to dioxin-induced prostaglandin e2 synthesis is resistant to the onset of neonatal hydronephrosis.
Hydronephrosis
Critical role of microsomal prostaglandin E synthase-1 in the hydronephrosis caused by lactational exposure to dioxin in mice.
Hydronephrosis
Predominant role of cytosolic phospholipase A2? in dioxin-induced neonatal hydronephrosis in mice.
Hyperalgesia
A novel role of prostaglandin E2 in neuropathic pain: blockade of microglial migration in the spinal cord.
Hyperalgesia
Downregulation of cytosolic prostaglandin E2 synthase results in decreased nociceptive behavior in rats.
Hyperalgesia
Expression of mPGES-1 and IP mRNA is reduced by LLLT in both subplantar and brain tissues in the model of peripheral inflammation induced by carrageenan.
Hyperalgesia
Interleukin-6 is a candidate molecule that transmits inflammatory information to the CNS.
Hyperalgesia
MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.
Hyperalgesia
Relevance of prostaglandins in migraine.
Hyperalgesia
Tricyclic 4,4-dimethyl-3,4-dihydrochromeno[3,4-d]imidazole derivatives as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors: SAR and in vivo efficacy in hyperalgesia pain model.
Hypercholesterolemia
Down-regulation of microsomal prostaglandin E2 synthase-1 in the infrapatellar fat pad of osteoarthritis patients with hypercholesterolemia.
Hyperlipidemias
Sex-dependent compensatory mechanisms preserve blood pressure homeostasis in prostacyclin receptor-deficient mice.
Hypernatremia
mPGES-1 Deletion Impairs Aldosterone Escape and Enhances Sodium Appetite.
Hypersensitivity
Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor.
Hypersensitivity
Platinum group elements in the environment: emissions and exposure.
Hypersensitivity
Prostaglandin E2 Produced by the Lung Augments the Effector Phase of Allergic Inflammation.
Hypersensitivity
Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1.
Hypersensitivity
The metallobiochemistry of ultratrace levels of platinum group elements in the rat.
Hypertension
Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1.
Hypertension
Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion.
Hypertension
Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion.
Hypertension
Microsomal prostaglandin E synthase-1 and blood pressure regulation.
Hypertension
Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury.
Hypertension
mPGES-1 (Microsomal Prostaglandin E Synthase-1) Mediates Vascular Dysfunction in Hypertension Through Oxidative Stress.
Hypertension
mPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP.
Hypertension
Myeloid Cell mPges-1 Deletion Attenuates Mortality Without Affecting Remodeling After Acute Myocardial Infarction in Mice.
Hypertension
Paradoxical Increase in Mortality and Rupture of Intracranial Aneurysms in Microsomal Prostaglandin E2 Synthase Type 1-Deficient Mice: Attenuation by Aspirin.
Hypertension
PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.
Hypertension
Pulmonary and cardiorenal cyclooxygenase-1 (COX-1), -2 (COX-2), and microsomal prostaglandin E synthase-1 (mPGES-1) and -2 (mPGES-2) expression in a hypertension model.
Hypertension
Regulation of YAP by Mammalian Target of Rapamycin Complex 1 in Endothelial Cells Controls Blood Pressure Through COX-2/mPGES-1/PGE2 Cascade.
Hypertension, Renovascular
Renal cortical regulation of COX-1 and functionally related products in early renovascular hypertension (rat).
Hypotension
Release of a prostaglandin E-like substance into mixed venous blood during endotoxin hypotension in cats.
Hypotension
Significant postictal hypotension: Expanding the spectrum of seizure-induced autonomic dysregulation.
Idiopathic Pulmonary Fibrosis
Microsomal prostaglandin E synthase-1 deficiency exacerbates pulmonary fibrosis induced by bleomycin in mice.
Infections
15d-PGJ? decreases PGE? synthesis in HBx-positive liver cells by interfering EGR1 binding to mPGES-1 promoter.
Infections
Blood COX-2 and PGES gene transcription during the peripartum period of dairy cows with normal puerperium or with uterine infection.
Infections
BVDV alters uterine prostaglandin production during pregnancy recognition in cows.
Infections
c-Jun N-terminal kinase-mediated stabilization of microsomal prostaglandin E2 synthase-1 mRNA regulates delayed microsomal prostaglandin E2 synthase-1 expression and prostaglandin E2 biosynthesis by cardiomyocytes.
Infections
Differential expression and regulation of microsomal prostaglandin E(2) synthase in human fetal membranes and placenta with infection and in cultured trophoblast cells.
Infections
EP2/4 Receptors Promote the Synthesis of PGE2 Increasing Tissue Damage in Bovine Endometrial Explants Induced by Escherichia coli.
Infections
Evidence in Favor of an Alternative Glucocorticoid Synthesis Pathway During Acute Experimental Chagas Disease.
Infections
Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression.
Infections
IL-1beta treatment does not co-ordinately up-regulate mPGES-1 and COX-2 mRNA expression, but results in higher degree of cellular and intracellular co-localization of their immunoreactive proteins in human placenta trophoblast cells.
Infections
Increased lethality and defective pulmonary clearance of Streptococcus pneumoniae in microsomal prostaglandin E synthase-1-knockout mice.
Infections
Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death.
Infections
Targeting eicosanoid pathways in the development of novel anti-influenza drugs.
Infections
The prostaglandin E2 receptor EP4 is integral to a positive feedback loop for prostaglandin E2 production in human macrophages infected with Mycobacterium tuberculosis.
Infections
The Prostaglandin E2-EP3 Receptor Axis Regulates Anaplasma phagocytophilum-Mediated NLRC4 Inflammasome Activation.
Infections
The Pseudomonas autoinducer N-(3-oxododecanoyl) homoserine lactone induces cyclooxygenase-2 and prostaglandin E2 production in human lung fibroblasts: implications for inflammation.
Infections
Upregulation of Cytokines and Differentiation of Th17 and Treg by Dendritic Cells: Central Role of Prostaglandin E2 Induced by Mycobacterium bovis.
Infertility
Comparative study of antiinflammatory drugs and sulphasalazine in relation to prostaglandin E and 19 hydroxylated prostaglandin E levels and human male fertility.
Infertility
Microsomal prostaglandin E synthase-1 (mPGES-1) is the primary form of PGES expressed by the primate periovulatory follicle.
Infertility
Prostaglandin concentrations in the semen of fertile men.
Inflammatory Bowel Diseases
Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1.
Inflammatory Bowel Diseases
Withdrawal: Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease: Evidence for involvement of the transcription factor Egr-1.
Influenza, Human
Identification of novel membrane-associated prostaglandin E synthase-1 (mPGES-1) inhibitors with anti-influenza activities in vitro.
Intellectual Disability
The SUDEP Risk Inventory: Association with postictal generalized EEG suppression.
Intestinal Neoplasms
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis.
Intestinal Neoplasms
Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation-associated colon carcinogenesis.
Intracranial Aneurysm
Paradoxical Increase in Mortality and Rupture of Intracranial Aneurysms in Microsomal Prostaglandin E2 Synthase Type 1-Deficient Mice: Attenuation by Aspirin.
Intracranial Aneurysm
PGE(2) -EP(2) receptor signaling in endothelium is activated by hemodynamic stress and induces cerebral aneurysm through an amplifying loop via NF-?B.
Intracranial Aneurysm
Upregulation of cyclooxygenase-2 (COX-2) and microsomal prostaglandin E2 synthase-1 (mPGES-1) in wall of ruptured human cerebral aneurysms: preliminary results.
Ischemic Stroke
A Promoter polymorphism (rs17222919, -1316T/G) of ALOX5AP is associated with intracerebral hemorrhage in Korean population.
Ischemic Stroke
The Role of mPGES-1 in Inflammatory Brain Diseases.
Ischemic Stroke
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Kidney Diseases
PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.
Kidney Failure, Chronic
Microsomal prostaglandin E synthase 1 deletion retards renal disease progression but exacerbates anemia in mice with renal mass reduction.
Kidney Failure, Chronic
Microsomal Prostaglandin E Synthase-1-Derived PGE2 Inhibits Vascular Smooth Muscle Cell Calcification.
Kidney Failure, Chronic
Prostaglandin E2 receptor EP2 mediates the effect of cyclooxygenase 2 on secondary parathyroid hyperplasia in end-stage renal disease.
Laryngeal Neoplasms
Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx.
Leukemia
MK886 inhibits the proliferation of HL-60 leukemia cells by suppressing the expression of mPGES-1 and reducing prostaglandin E2 synthesis.
Leukemia
[Effect of mPGES-1 Inhibitor MK886 on Apoptosis and Drug Resistance of HL-60/A Cells].
Leukemia
[Effect of mPGES-1 inhibitor MK886 on cell cycle of leukemia HL-60 cells].
Leukemia
[Effects of shRNA Targeting mPGES-1 on Tumorigenicity of K562 Cells in Nude Mice In Vivo].
Leukemia, Myeloid, Acute
MK886 inhibits the proliferation of HL-60 leukemia cells by suppressing the expression of mPGES-1 and reducing prostaglandin E2 synthesis.
Leukemia, Myeloid, Acute
[Effect of mPGES-1 inhibitor MK886 on cell cycle of leukemia HL-60 cells].
Leydig Cell Tumor
COX-2 gene polymorphisms and protein expression in renomedullary interstitial cell tumors.
Liver Diseases
Pathophysiological role of prostaglandin E synthases in liver diseases.
Liver Neoplasms
Expression of microsomal prostaglandin E2 synthase-1 and its role in human hepatocellular carcinoma.
Long QT Syndrome
Prevention of sudden unexpected death in epilepsy: current status and future perspectives.
Lung Injury
Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice.
Lung Neoplasms
Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model.
Lung Neoplasms
Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.
Lung Neoplasms
Clinical implications of microsomal prostaglandin e synthase-1 overexpression in human non-small-cell lung cancer.
Lung Neoplasms
Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer.
Lung Neoplasms
Ellagitannins from Punica granatum leaves suppress microsomal prostaglandin E synthase-1 expression and induce lung cancer cells to undergo apoptosis.
Lung Neoplasms
Expression of Cytosolic Phospholipase A2 (cPLA2)-Arachidonic Acid (AA)-Cyclooxygenase-2 (COX-2) Pathway Factors in Lung Cancer Patients and Its Implication in Lung Cancer Early Detection and Prognosis.
Lung Neoplasms
Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines.
Lung Neoplasms
Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer.
Lung Neoplasms
Inhibition of mPGES-1 or COX-2 Results in Different Proteomic and Lipidomic Profiles in A549 Lung Cancer Cells.
Lung Neoplasms
Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells.
Lung Neoplasms
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction.
Lung Neoplasms
miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells.
Lung Neoplasms
miR-708-5p targets oncogenic prostaglandin E2 production to suppress a pro-tumorigenic phenotype in lung cancer cells.
Lung Neoplasms
mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines.
Lung Neoplasms
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
Lung Neoplasms
Proteomics-Based Characterization of miR-574-5p Decoy to CUGBP1 Suggests Specificity for mPGES-1 Regulation in Human Lung Cancer Cells.
Lung Neoplasms
Revealing the effect of 6-gingerol, 6-shogaol and curcumin on mPGES-1, GSK-3? and ?-catenin pathway in A549 cell line.
Lung Neoplasms
Stabilization of PTGES by deubiquitinase USP9X promotes metastatic features of lung cancer via PGE2 signaling.
Lung Neoplasms
Upregulation of COX-2 in the lung cancer promotes overexpression of multidrug resistance protein 4 (MRP4) via PGE2-dependent pathway.
Lymphatic Metastasis
PGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression.
Lymphoma
Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphoma.
Medulloblastoma
Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets.
Melanoma
Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression.
Melanoma
The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.
Melanoma, Experimental
Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis.
Metabolic Syndrome
PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.
Metabolic Syndrome
Prostaglandin E synthase 2 (PTGES2) Arg298His polymorphism and parameters of the metabolic syndrome.
Miosis
Atropine-antagonized miosis induced in the goat by intravenous infusions of prostaglandin E (PGE1 and PGE2).
Mucositis
Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study.
Multiple Sclerosis
Endothelial Microsomal Prostaglandin E Synthetase-1 Upregulates Vascularity and Endothelial Interleukin-1? in Deteriorative Progression of Experimental Autoimmune Encephalomyelitis.
Multiple Sclerosis
Microsomal prostaglandin E synthase-1 aggravates inflammation and demyelination in a mouse model of multiple sclerosis.
Multiple Sclerosis
Microsomal Prostaglandin E Synthase-1 Facilitates an Intercellular Interaction between CD4? T Cells through IL-1? Autocrine Function in Experimental Autoimmune Encephalomyelitis.
Multiple Sclerosis
Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis.
Myocardial Infarction
An Update of Microsomal Prostaglandin E Synthase-1 and PGE2 Receptors in Cardiovascular Health and Diseases.
Myocardial Infarction
Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice.
Myocardial Infarction
Lack of microsomal prostaglandin E(2) synthase-1 in bone marrow-derived myeloid cells impairs left ventricular function and increases mortality after acute myocardial infarction.
Myocardial Infarction
Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction.
Myocardial Infarction
Myeloid Cell mPges-1 Deletion Attenuates Mortality Without Affecting Remodeling After Acute Myocardial Infarction in Mice.
Myocardial Infarction
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Myositis
Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis.
Myositis
Microsomal prostaglandin e synthase-1 in rheumatic diseases.
Nasal Polyps
Role of prostaglandin D2 and E2 terminal synthases in chronic rhinosinusitis.
Neoplasm Metastasis
Clinical implications of microsomal prostaglandin e synthase-1 overexpression in human non-small-cell lung cancer.
Neoplasm Metastasis
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis.
Neoplasm Metastasis
Direct Melanoma Cell Contact Induces Stromal Cell Autocrine Prostaglandin E2-EP4 Receptor Signaling That Drives Tumor Growth, Angiogenesis, and Metastasis.
Neoplasm Metastasis
Expression of Cytosolic Phospholipase A2 (cPLA2)-Arachidonic Acid (AA)-Cyclooxygenase-2 (COX-2) Pathway Factors in Lung Cancer Patients and Its Implication in Lung Cancer Early Detection and Prognosis.
Neoplasm Metastasis
Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis.
Neoplasm Metastasis
Microsomal prostaglandin E synthase-1 promotes lung metastasis via SDF-1/CXCR4-mediated recruitment of CD11b+Gr1+MDSCs from bone marrow.
Neoplasm Metastasis
mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.
Neoplasm Metastasis
PGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression.
Neoplasm Metastasis
PTGES/PGE2 signaling links immunosuppression and lung metastasis in Gprc5a-knockout mouse model.
Neoplasm Metastasis
Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells.
Neoplasm Metastasis
Stabilization of PTGES by deubiquitinase USP9X promotes metastatic features of lung cancer via PGE2 signaling.
Neoplasm Metastasis
[Role of mPGES-1 in the occurrence, progression, metastasis and invasion of hepatocellular carcinoma].
Neoplasms
15-deoxy-Delta12,14-prostaglandin J2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells.
Neoplasms
15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in Nu/Nu mice.
Neoplasms
15d-PGJ? decreases PGE? synthesis in HBx-positive liver cells by interfering EGR1 binding to mPGES-1 promoter.
Neoplasms
A study of prostaglandin E2, parathormone, and response to indomethacin in patients with hypercalcemia of malignancy.
Neoplasms
AH6809 decreases production of inflammatory mediators by PGE2 - EP2 - cAMP signaling pathway in an experimentally induced pure cerebral concussion in rats.
Neoplasms
Allogenic Pure Platelet-Rich Plasma Therapy for Adhesive Capsulitis: A Bed-to-Bench Study With Propensity Score Matching Using a Corticosteroid Control Group.
Neoplasms
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
Neoplasms
Anti-inflammatory activity of monogalactosyldiacylglycerol in human articular cartilage in vitro: activation of an anti-inflammatory cyclooxygenase-2 (COX-2) pathway.
Neoplasms
Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation.
Neoplasms
Arsenic-induced testicular toxicity in Gallus gallus: Expressions of inflammatory cytokines and heat shock proteins.
Neoplasms
Association between adenomatosis polyposis coli functional status and microsomal prostaglandin E synthase-1 expression in colorectal cancer.
Neoplasms
Cancer-induced anorexia in tumor-bearing mice is dependent on cyclooxygenase-1.
Neoplasms
Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway.
Neoplasms
Characterization of microsomal prostaglandin E synthase 1 inhibitors.
Neoplasms
Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.
Neoplasms
Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer.
Neoplasms
Clinical data mining reveals analgesic effects of lapatinib in cancer patients.
Neoplasms
Clinical implications of microsomal prostaglandin e synthase-1 overexpression in human non-small-cell lung cancer.
Neoplasms
Clinical significance of prostaglandin E synthase expression in gastric cancer tissue.
Neoplasms
Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer.
Neoplasms
Comparative Analysis of Peritoneum and Tumor Eicosanoids and Pathways in Advanced Ovarian Cancer.
Neoplasms
Conditioned media from adipose-tissue-derived mesenchymal stem cells downregulate degradative mediators induced by interleukin-1? in osteoarthritic chondrocytes.
Neoplasms
Contribution of membrane-associated prostaglandin E2 synthase to bone resorption.
Neoplasms
Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis.
Neoplasms
Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4.
Neoplasms
Corticosterone suppresses IL-1?-induced mPGE2 expression through regulation of the 11?-HSD1 bioactivity of synovial fibroblasts in vitro.
Neoplasms
COX-2 gene polymorphisms and protein expression in renomedullary interstitial cell tumors.
Neoplasms
COX-2 Limits Prostanoid Production in Activated HUVECs and Is a Source of PGH2 for Transcellular Metabolism to PGE2 by Tumor Cells.
Neoplasms
COX-2 signaling and cancer: new players in old arena.
Neoplasms
COX-2, mPGES-1 and EP2 receptor immunohistochemical expression in canine and feline malignant mammary tumours.
Neoplasms
COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset.
Neoplasms
CRISPR/Cas9-based liver-derived reporter cells for screening of mPGES-1 inhibitors.
Neoplasms
Crystal Structures of mPGES-1 Inhibitor Complexes Form a Basis for the Rational Design of Potent Analgesic and Anti-Inflammatory Therapeutics.
Neoplasms
Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer.
Neoplasms
Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis.
Neoplasms
Cysteinyl leukotriene-receptor-1 antagonists interfere with PGE2 synthesis by inhibiting mPGES-1 activity.
Neoplasms
Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2.
Neoplasms
Dimethylcelecoxib inhibits mPGES-1 promoter activity by influencing EGR1 and NF-?B.
Neoplasms
Dioscorea japonica extract down-regulates prostaglandin E2 synthetic pathway and induces apoptosis in lung cancer cells.
Neoplasms
Discovery of 3-hydroxy-3-pyrrolin-2-one-based mPGES-1 inhibitors using a multi-step virtual screening protocol.
Neoplasms
Discovery of novel, non-acidic mPGES-1 inhibitors by virtual screening with a multistep protocol.
Neoplasms
Does dienogest influence the inflammatory response of endometriotic cells? A systematic review.
Neoplasms
Down-regulation of microsomal prostaglandin E2 synthase-1 in the infrapatellar fat pad of osteoarthritis patients with hypercholesterolemia.
Neoplasms
Effect of sphingosine kinase 1 inhibition on blood pressure.
Neoplasms
Effect of vitamin C on azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated early colon cancer in mice.
Neoplasms
Effects of antirheumatic treatments on the prostaglandin E2 biosynthetic pathway.
Neoplasms
Effects of Excess Manganese on the Oxidative Status, and the Expression of Inflammatory Factors and Heat Shock Proteins in Cock Kidneys.
Neoplasms
EGFR signaling upregulates expression of microsomal prostaglandin E synthase-1 in cancer cells leading to enhanced tumorigenicity.
Neoplasms
Ellagitannins from Punica granatum leaves suppress microsomal prostaglandin E synthase-1 expression and induce lung cancer cells to undergo apoptosis.
Neoplasms
Engineering of a novel hybrid enzyme: an anti-inflammatory drug target with triple catalytic activities directly converting arachidonic acid into the inflammatory prostaglandin E2.
Neoplasms
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.
Neoplasms
Enriched environment housing improved the laying hen's resistance to transport stress via modulating the heat shock protective response and inflammation.
Neoplasms
Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor-stroma drug targeting.
Neoplasms
Expression and contribution of three different isoforms of prostaglandin E synthase in the bovine endometrium.
Neoplasms
Expression and regulation of microsomal prostaglandin E synthase-1 in human osteoarthritic cartilage and chondrocytes.
Neoplasms
Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine.
Neoplasms
Expression of cyclooxygenase-1/-2, microsomal prostaglandin-E synthase-1 and E-prostanoid receptor 2 and regulation of inflammatory mediators by PGE(2) in the amoeboid microglia in hypoxic postnatal rats and murine BV-2 cells.
Neoplasms
Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma.
Neoplasms
Expression of cyclooxygenase-2 and microsomal prostaglandin-E synthase in amoeboid microglial cells in the developing brain and effects of cyclooxygenase-2 neutralization on BV-2 microglial cells.
Neoplasms
Expression of Cytosolic Phospholipase A2 (cPLA2)-Arachidonic Acid (AA)-Cyclooxygenase-2 (COX-2) Pathway Factors in Lung Cancer Patients and Its Implication in Lung Cancer Early Detection and Prognosis.
Neoplasms
Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines.
Neoplasms
Expression of microsomal prostaglandin E2 synthase-1 and its role in human hepatocellular carcinoma.
Neoplasms
Expression of prostaglandin E synthase in Barrett's cancer.
Neoplasms
Expression of prostaglandin e synthases in periodontitis immunolocalization and cellular regulation.
Neoplasms
Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma.
Neoplasms
Expression of proteins related to prostaglandin E2 biosynthesis is increased in human gastric cancer and during gastric carcinogenesis.
Neoplasms
Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy.
Neoplasms
Genes for prostaglandin synthesis, transport and inactivation are differentially expressed in human uterine tissues, and the prostaglandin F synthase AKR1B1 is induced in myometrial cells by inflammatory cytokines.
Neoplasms
Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis.
Neoplasms
Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice.
Neoplasms
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis.
Neoplasms
Genetic-deletion of Cyclooxygenase-2 Downstream Prostacyclin Synthase Suppresses Inflammatory Reactions but Facilitates Carcinogenesis, unlike Deletion of Microsomal Prostaglandin E Synthase-1.
Neoplasms
GPER signalling in both cancer-associated fibroblasts and breast cancer cells mediates a feedforward IL1?/IL1R1 response.
Neoplasms
Growth inhibitory effect of polyunsaturated fatty acids (PUFAs) on colon cancer cells via their growth inhibitory metabolites and fatty acid composition changes.
Neoplasms
Hyperplastic gastric tumors with spasmolytic polypeptide-expressing metaplasia caused by tumor necrosis factor-alpha-dependent inflammation in cyclooxygenase-2/microsomal prostaglandin E synthase-1 transgenic mice.
Neoplasms
Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis.
Neoplasms
Hypoxia-inducible factor-2? is essential in activating the COX2/mPGES-1/PGE2 signaling axis in colon cancer.
Neoplasms
ICV vs. VMH injection of leptin: comparative effects on hypothalamic gene expression.
Neoplasms
Identification and development of mPGES-1 inhibitors: where we are at?
Neoplasms
Identification of 2-(thiophen-2-yl)acetic Acid-Based Lead Compound for mPGES-1 Inhibition.
Neoplasms
Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers.
Neoplasms
Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target.
Neoplasms
Identification of novel microsomal prostaglandin E2 synthase-1 (mPGES-1) lead inhibitors from Fragment Virtual Screening.
Neoplasms
Identification of novel mPGES-1 inhibitors through screening of a chemical library.
Neoplasms
Immunohistochemical Demonstration of Membrane-bound Prostaglandin E(2) Synthase-1 in Papillary Thyroid Carcinoma.
Neoplasms
Immunohistochemical Expression of COX-2, mPGES and EP2 Receptor in Normal and Reactive Canine Bone and in Canine Osteosarcoma.
Neoplasms
Impact of Cyclooxygenase-2 1195 G-Carrier Genotype Associated with Intestinal Metaplasia and Endoscopic Findings Based on Kyoto Classification.
Neoplasms
Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer.
Neoplasms
Increase in PGE2 biosynthesis induces a Bax dependent apoptosis correlated to patients' survival in glioblastoma multiforme.
Neoplasms
Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in brain of HIV-1 transgenic rats.
Neoplasms
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer.
Neoplasms
Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer.
Neoplasms
Induction of human microsomal prostaglandin E synthase 1 by activated oncogene RhoA GTPase in A549 human epithelial cancer cells.
Neoplasms
Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling.
Neoplasms
Inflammatory and cytotoxic effects of bifenthrin in primary microglia and organotypic hippocampal slice cultures.
Neoplasms
Inflammatory and oxidative mechanisms potentiate bifenthrin-induced neurological alterations and anxiety-like behavior in adult rats.
Neoplasms
Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis.
Neoplasms
Inhibition of IFN-gamma induction of class II MHC genes by cAMP and prostaglandins.
Neoplasms
Inhibition of microsomal prostaglandin E synthase-1 as targeted therapy in cancer treatment.
Neoplasms
Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth.
Neoplasms
Inhibition of mPGES-1 or COX-2 Results in Different Proteomic and Lipidomic Profiles in A549 Lung Cancer Cells.
Neoplasms
Innate immune reaction in response to seizures: implications for the neuropathology associated with epilepsy.
Neoplasms
Instability of a dinucleotide repeat in the 3'-untranslated region (UTR) of the microsomal prostaglandin E synthase-1 (mPGES-1) gene in microsatellite instability-high (MSI-H) colorectal carcinoma.
Neoplasms
Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE2.
Neoplasms
Interleukin-8 (IL-8) overexpression in astrocytomas is induced by prostaglandin E2 (PGE2) and is associated to the transcription factors CCAAT enhancer binding protein-beta (C/EBP-?) and C/EBP Homologous Protein (CHOP).
Neoplasms
Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma.
Neoplasms
Kruppel-like Factor 5 Transcription Factor Promotes Microsomal Prostaglandin E2 Synthase 1 Gene Transcription in Breast Cancer.
Neoplasms
Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and -186 expression: Novel mechanism of VEGF modulation in prostate cancer.
Neoplasms
Linking of mPGES-1 and iNOS activates stem-like phenotype in EGFR-driven epithelial tumor cells.
Neoplasms
Lipopolysaccharides, cytokines, and nitric oxide affect secretion of prostaglandins and leukotrienes by bovine mammary gland epithelial cells.
Neoplasms
Localization of prostaglandin E2 synthases and E-prostanoid receptors in the spinal cord in a rat model of neuropathic pain.
Neoplasms
Loss of 15-Hydroxyprostaglandin Dehydrogenase Increases Prostaglandin E2 in Pancreatic Tumors.
Neoplasms
Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras(G12D/+) mice.
Neoplasms
Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2.
Neoplasms
Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis.
Neoplasms
Microsomal prostaglandin E synthase 1 deletion retards renal disease progression but exacerbates anemia in mice with renal mass reduction.
Neoplasms
Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells.
Neoplasms
Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients.
Neoplasms
Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer.
Neoplasms
Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis.
Neoplasms
Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease.
Neoplasms
Microsomal Prostaglandin E Synthase-1 Inhibits PTEN and Promotes Experimental Cholangiocarcinogenesis and Tumor Progression.
Neoplasms
Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis.
Neoplasms
Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1.
Neoplasms
Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/?-catenin signaling axis.
Neoplasms
Microsomal prostaglandin E synthase-1 promotes lung metastasis via SDF-1/CXCR4-mediated recruitment of CD11b+Gr1+MDSCs from bone marrow.
Neoplasms
Microsomal Prostaglandin E2 Synthase-1 as a New Macromolecular Drug Target in the Prevention of ?nflammation and Cancer.
Neoplasms
Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy.
Neoplasms
Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.
Neoplasms
Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway.
Neoplasms
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction.
Neoplasms
miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells.
Neoplasms
miR-708-5p targets oncogenic prostaglandin E2 production to suppress a pro-tumorigenic phenotype in lung cancer cells.
Neoplasms
MK886 inhibits the proliferation of HL-60 leukemia cells by suppressing the expression of mPGES-1 and reducing prostaglandin E2 synthesis.
Neoplasms
Modulation of inflammatory response by selective inhibition of cyclooxygenase-1 and cyclooxygenase-2 in acute kidney injury.
Neoplasms
Molecular docking and competitive binding study discovered different binding modes of microsomal prostaglandin E synthase-1 inhibitors.
Neoplasms
Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials.
Neoplasms
mPGES-1 as a novel target for arthritis.
Neoplasms
mPGES-1 as a target for cancer suppression A comprehensive invited review "Phospholipase A(2) and lipid mediators"
Neoplasms
mPGES-1 expression in non-cancerous liver tissue impacts on postoperative recurrence of HCC.
Neoplasms
mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.
Neoplasms
MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer.
Neoplasms
mPGES-1-expressing bone marrow-derived cells enhance tumor growth and angiogenesis in mice.
Neoplasms
Multifaceted roles of PGE2 in inflammation and cancer.
Neoplasms
NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
Neoplasms
Necrosis in DU145 prostate cancer spheroids induces COX-2/mPGES-1-derived PGE2 to promote tumor growth and to inhibit T cell activation.
Neoplasms
NF-kappaB induces PGE(2)-synthesizing enzymes in neurons.
Neoplasms
Nitric Oxide and PGE-2 Cross-Talk in EGFR-Driven Epithelial Tumor Cells.
Neoplasms
Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation-associated colon carcinogenesis.
Neoplasms
Nonsteroidal anti-inflammatory drug-activated gene-1 expression inhibits urethane-induced pulmonary tumorigenesis in transgenic mice.
Neoplasms
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression.
Neoplasms
Oxytocin and tumor necrosis factor alpha stimulate expression of prostaglandin E2 synthase and secretion of prostaglandin E2 by luminal epithelial cells of the porcine endometrium during early pregnancy.
Neoplasms
Peripheral lipopolysaccharide administration induces cytokine mRNA expression in the viscera and brain of fever-refractory mice lacking microsomal prostaglandin E synthase-1.
Neoplasms
PGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression.
Neoplasms
Pharmacological inhibition of microsomal prostaglandin e synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis.
Neoplasms
Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25+ /CD54+ NK cells.
Neoplasms
Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis.
Neoplasms
Progranulin Protects Hippocampal Neurogenesis via Suppression of Neuroinflammatory Responses Under Acute Immune Stress.
Neoplasms
Prostaglandin e synthase: a novel drug target for inflammation and cancer.
Neoplasms
Prostaglandin E2 produced by inducible COX-2 and mPGES-1 promoting cancer cell proliferation in vitro and in vivo.
Neoplasms
Prostaglandin Gbetagamma signaling stimulates gastrulation movements by limiting cell adhesion through Snai1a stabilization.
Neoplasms
Prostaglandin synthases influence thyroid follicular cell proliferation but not carcinogenesis in rats initiated with N-bis(2-hydroxypropyl)nitrosamine.
Neoplasms
Prostaglandins in cancer cell adhesion, migration, and invasion.
Neoplasms
Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression.
Neoplasms
Receptor and enzyme expression for prostanoid metabolism in colorectal cancer related to tumor tissue PGE2.
Neoplasms
Regulation of Human Microsomal Prostaglandin E Synthase-1 by IL-1? requires a Distal Enhancer Element with a Unique Role for C/EBP?
Neoplasms
Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2.
Neoplasms
Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2.
Neoplasms
Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice.
Neoplasms
Regulatory roles of PGE2 in LPS-induced tissue damage in bovine endometrial explants.
Neoplasms
Revealing the effect of 6-gingerol, 6-shogaol and curcumin on mPGES-1, GSK-3? and ?-catenin pathway in A549 cell line.
Neoplasms
Role of TLR-4 in liver macrophage and endothelial cell responsiveness during acute endotoxemia.
Neoplasms
Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells.
Neoplasms
SAR studies on curcumin's pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase.
Neoplasms
Selective PGE2 Suppression Inhibits Colon Carcinogenesis and Modifies Local Mucosal Immunity.
Neoplasms
Selenium alleviates cadmium-induced inflammation and meat quality degradation via antioxidant and anti-inflammation in chicken breast muscles.
Neoplasms
Signal pathways involved in the regulation of prostaglandin E synthase-1 in human gingival fibroblasts.
Neoplasms
Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx.
Neoplasms
Sonlicromanol's active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth.
Neoplasms
Stabilization of PTGES by deubiquitinase USP9X promotes metastatic features of lung cancer via PGE2 signaling.
Neoplasms
Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport.
Neoplasms
Sulforaphane inhibits prostaglandin E2 synthesis by suppressing microsomal prostaglandin E synthase 1.
Neoplasms
Synthesis and biological evaluation of novel myrtucommulones and structural analogues that target mPGES-1 and 5-lipoxygenase.
Neoplasms
Targeted over-expression of mPGES-1 and elevated PGE2 production is not sufficient for lung tumorigenesis in mice.
Neoplasms
Targeting mPGES-1 by a Combinatorial Approach: Identification of the Aminobenzothiazole Scaffold to Suppress PGE2 Levels.
Neoplasms
Tenacissoside H exerts an anti-inflammatory effect by regulating the nf-?b and p38 pathways in zebrafish.
Neoplasms
The Antagonistic Effect of Selenium on Cadmium-Induced Damage and mRNA Levels of Selenoprotein Genes and Inflammatory Factors in Chicken Kidney Tissue.
Neoplasms
The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.
Neoplasms
The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis.
Neoplasms
The role of heat shock protein 70 in oxidant stress and inflammatory injury in quail spleen induced by cold stress.
Neoplasms
The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES are all overexpressed in human gliomas.
Neoplasms
Transcriptional regulation of microsomal prostaglandin E synthase 1 by the proto-oncogene, c-myc, in the pathogenesis of inflammation and cancer.
Neoplasms
Transcriptional regulation of mPGES1 in Cancer: an alternative approach to drug discovery?
Neoplasms
Triclosan reduces microsomal prostaglandin E synthase-1 expression in human gingival fibroblasts.
Neoplasms
Tumor cells induce COX-2 and mPGES-1 expression in microvascular endothelial cells mainly by means of IL-1 receptor activation.
Neoplasms
[Prostaglandin E2 synthases]
Neoplasms
[Role of mPGES-1 in the occurrence, progression, metastasis and invasion of hepatocellular carcinoma].
Neuralgia
Localization of prostaglandin E2 synthases and E-prostanoid receptors in the spinal cord in a rat model of neuropathic pain.
Neuralgia
Membrane-associated prostaglandin E synthase-1 is required for neuropathic pain.
Neuroblastoma
Calcium Ions Stimulate the Hyperphosphorylation of Tau by Activating Microsomal Prostaglandin E Synthase 1.
Neuroblastoma
COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset.
Neuroblastoma
Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor-stroma drug targeting.
Neuroblastoma
Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth.
Neuroblastoma
Loading into nanoparticles improves quercetin's efficacy in preventing neuroinflammation induced by oxysterols.
Neuroblastoma
Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport.
Neuroblastoma
Targeting mPGES-1 as a New Strategy against Neuroblastoma.
Neuroblastoma
Targeting the COX/mPGES-1/PGE2 Pathway in Neuroblastoma.
Neurodegenerative Diseases
Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease.
Neuroinflammatory Diseases
Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation.
Neuroinflammatory Diseases
Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: Possible involvement of NF-?B and p38 MAPK inhibition.
Neuroinflammatory Diseases
CCAAT/Enhancer binding protein ? regulates prostaglandin E synthase expression and prostaglandin E2 production in activated microglial cells.
Neuroinflammatory Diseases
Impaired lipid metabolism markers to assess the risk of neuroinflammation in autism spectrum disorder.
Neuroinflammatory Diseases
Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells.
Neuroinflammatory Diseases
Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2.
Neuroinflammatory Diseases
Roles of prostaglandin synthesis in excitotoxic brain diseases.
Obesity
Down-regulation of microsomal prostaglandin E2 synthase-1 in adipose tissue by high-fat feeding.
Obesity
Invalidation of Microsomal Prostaglandin E Synthase-1 (mPGES-1) Reduces Diet-Induced Low-Grade Inflammation and Adiposity.
Obesity
Prostaglandin E synthase 2 (PTGES2) Arg298His polymorphism and parameters of the metabolic syndrome.
Obstetric Labor, Premature
Change in prostaglandin E synthases (PGESs) in microsomal PGES-1 knockout mice in a preterm delivery model.
Obstetric Labor, Premature
Differential expression and regulation of microsomal prostaglandin E(2) synthase in human fetal membranes and placenta with infection and in cultured trophoblast cells.
Obstetric Labor, Premature
Expression and localization of prostaglandin E synthase isoforms in human fetal membranes in term and preterm labor.
Odontogenic Cysts
Odontogenic cyst growth and prostaglandin-induced bone resorption.
Oligodendroglioma
The terminal prostaglandin synthases mPGES-1, mPGES-2, and cPGES are all overexpressed in human gliomas.
Osteoarthritis
A randomized clinical efficacy study targeting mPGES1 or EP4 in dogs with spontaneous osteoarthritis.
Osteoarthritis
Association of microsomal prostaglandin E synthase 1 deficiency with impaired fracture healing, but not with bone loss or osteoarthritis, in mouse models of skeletal disorders.
Osteoarthritis
BCP crystals increase prostacyclin production and upregulate the prostacyclin receptor in OA synovial fibroblasts: potential effects on mPGES1 and MMP-13.
Osteoarthritis
Corticosterone suppresses IL-1?-induced mPGE2 expression through regulation of the 11?-HSD1 bioactivity of synovial fibroblasts in vitro.
Osteoarthritis
Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.
Osteoarthritis
Down-regulation of microsomal prostaglandin E2 synthase-1 in the infrapatellar fat pad of osteoarthritis patients with hypercholesterolemia.
Osteoarthritis
Eicosanoids, osteoarthritis, and crystal deposition diseases.
Osteoarthritis
Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis.
Osteoarthritis
Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1?-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes.
Osteoarthritis
Mechanical stress and prostaglandin E(2) synthesis in cartilage.
Osteoarthritis
Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis.
Osteoarthritis
Microsomal prostaglandin e synthase-1 in rheumatic diseases.
Osteoarthritis
Prostaglandin E synthase in the pathophysiology of arthritis.
Osteoarthritis
Prostaglandin e2 synthase-1 inhibitors as potential treatment for osteoarthritis: patent highlight.
Osteoarthritis
Prostaglandin E2 synthesis in cartilage explants under compression: mPGES-1 is a mechanosensitive gene.
Osteoarthritis
Regulation of gene expression by MF63, a selective inhibitor of microsomal PGE synthase 1 (mPGES1) in human osteoarthritic chondrocytes.
Osteoarthritis
Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways.
Osteolysis
A mutation of cysteine 46 in IKK-? promotes mPGES-1 and caveolin-1 expression to exacerbate osteoclast differentiation and osteolysis.
Osteosarcoma
Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells.
Osteosarcoma
Immunohistochemical Expression of COX-2, mPGES and EP2 Receptor in Normal and Reactive Canine Bone and in Canine Osteosarcoma.
Ovarian Neoplasms
Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.
Pancreatic Neoplasms
Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers.
Papilloma
Elevated prostaglandin E2 level via cPLA2--COX-2--mPGES-1 pathway involved in bladder carcinogenesis induced by terephthalic acid-calculi in Wistar rats.
Papilloma
Expression of COX-1, COX-2 and mPGES-1 in penile and preputial papillomas and squamous cell carcinomas in the horse.
Papilloma
The expression pattern of prostaglandin E synthase and EP receptor isoforms in normal mouse skin and preinvasive skin neoplasms.
Paralysis
Endothelial Microsomal Prostaglandin E Synthetase-1 Upregulates Vascularity and Endothelial Interleukin-1? in Deteriorative Progression of Experimental Autoimmune Encephalomyelitis.
Parkinson Disease
Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson's disease.
Pellagra
Niacin deficiency and cutaneous immunity.
Pellagra
Prostaglandin E? is critical for the development of niacin-deficiency-induced photosensitivity via ROS production.
Periodontitis
Expression of prostaglandin e synthases in periodontitis immunolocalization and cellular regulation.
Periodontitis
Inhibition of microsomal prostaglandin E synthase-1 by aminothiazoles decreases prostaglandin E2 synthesis in vitro and ameliorates experimental periodontitis in vivo.
Periodontitis
Membrane-bound prostaglandin E synthase-1-mediated prostaglandin E2 production by osteoblast plays a critical role in lipopolysaccharide-induced bone loss associated with inflammation.
Peripheral Nerve Injuries
A novel role of prostaglandin E2 in neuropathic pain: blockade of microglial migration in the spinal cord.
Peritoneal Fibrosis
Enhanced mPGES-1 Contributes to PD-Related Peritoneal Fibrosis via Activation of the NLRP3 Inflammasome.
Peritonitis
Inhibition of mPGES-1 attenuates efficient resolution of acute inflammation by enhancing CX3CL1 expression.
Peritonitis
Roles of mPGES-1, an inducible prostaglandin E synthase, in enhancement of LPS-induced lymphangiogenesis in a mouse peritonitis model.
Pleurisy
Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1.
Pleurisy
Interaction between cyclooxygenase (COX)-1- and COX-2-products modulates COX-2 expression in the late phase of acute inflammation.
Pneumonia
Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer.
Pneumonia
DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.
Pneumonia
Prostaglandin E(2) exerts homeostatic regulation of pulmonary vascular remodeling in allergic airway inflammation.
Pneumonia
Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes.
Pneumonia, Bacterial
Increased lethality and defective pulmonary clearance of Streptococcus pneumoniae in microsomal prostaglandin E synthase-1-knockout mice.
Pneumonia, Pneumococcal
Increased lethality and defective pulmonary clearance of Streptococcus pneumoniae in microsomal prostaglandin E synthase-1-knockout mice.
Polymyositis
Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis.
Polyuria
Mice Lacking mPGES-1 Are Resistant to Lithium-Induced Polyuria.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Regulation of mPGES-1 composition and cell growth via the MAPK signaling pathway in jurkat cells.
prostaglandin-e synthase deficiency
Association of microsomal prostaglandin E synthase 1 deficiency with impaired fracture healing, but not with bone loss or osteoarthritis, in mouse models of skeletal disorders.
prostaglandin-e synthase deficiency
Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion.
prostaglandin-e synthase deficiency
Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile.
prostaglandin-e synthase deficiency
Gene Deletion of Microsomal Prostaglandin E Synthase-1 Suppresses Chemically Induced Skin Carcinogenesis.
prostaglandin-e synthase deficiency
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis.
prostaglandin-e synthase deficiency
Genetic-deletion of Cyclooxygenase-2 Downstream Prostacyclin Synthase Suppresses Inflammatory Reactions but Facilitates Carcinogenesis, unlike Deletion of Microsomal Prostaglandin E Synthase-1.
prostaglandin-e synthase deficiency
Involvement of prostacyclin synthase in high-fat-diet-induced obesity.
prostaglandin-e synthase deficiency
Membrane-bound prostaglandin E synthase-1-mediated prostaglandin E2 production by osteoblast plays a critical role in lipopolysaccharide-induced bone loss associated with inflammation.
prostaglandin-e synthase deficiency
Microsomal prostaglandin E synthase-1 deficiency exacerbates pulmonary fibrosis induced by bleomycin in mice.
prostaglandin-e synthase deficiency
Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway.
prostaglandin-e synthase deficiency
Microsomal prostaglandin E synthase-1 gene deletion impairs neuro-immune circuitry of the cholinergic anti-inflammatory pathway in endotoxaemic mouse spleen.
prostaglandin-e synthase deficiency
Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis.
prostaglandin-e synthase deficiency
Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation-associated colon carcinogenesis.
prostaglandin-e synthase deficiency
Paradoxical Increase in Mortality and Rupture of Intracranial Aneurysms in Microsomal Prostaglandin E2 Synthase Type 1-Deficient Mice: Attenuation by Aspirin.
prostaglandin-e synthase deficiency
Reduced T cell-dependent humoral immune response in microsomal prostaglandin E synthase-1 null mice is mediated by nonhematopoietic cells.
prostaglandin-e synthase deficiency
Role of microsomal prostaglandin E synthase 1 in the kidney.
prostaglandin-e synthase deficiency
The impact of microsomal prostaglandin e synthase 1 on blood pressure is determined by genetic background.
prostaglandin-endoperoxide synthase deficiency
Cyclooxygenase-1 and -2 enzymes differentially regulate the brain upstream NF-kappa B pathway and downstream enzymes involved in prostaglandin biosynthesis.
prostaglandin-i synthase deficiency
Genetic-deletion of Cyclooxygenase-2 Downstream Prostacyclin Synthase Suppresses Inflammatory Reactions but Facilitates Carcinogenesis, unlike Deletion of Microsomal Prostaglandin E Synthase-1.
Prostatic Hyperplasia
Expression and significance of microsomal prostaglandin synthase-1 (mPGES-1) and Beclin-1 in the development of prostate cancer.
Prostatic Neoplasms
Expression and significance of microsomal prostaglandin synthase-1 (mPGES-1) and Beclin-1 in the development of prostate cancer.
Prostatic Neoplasms
Linking microsomal prostaglandin E Synthase-1/PGE-2 pathway with miR-15a and -186 expression: Novel mechanism of VEGF modulation in prostate cancer.
Prostatic Neoplasms
Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells.
Prostatic Neoplasms
Microsomal prostaglandin E synthase-1 promotes lung metastasis via SDF-1/CXCR4-mediated recruitment of CD11b+Gr1+MDSCs from bone marrow.
Prostatic Neoplasms
mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.
Prostatic Neoplasms
Necrosis in DU145 prostate cancer spheroids induces COX-2/mPGES-1-derived PGE2 to promote tumor growth and to inhibit T cell activation.
Prostatic Neoplasms
Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells.
Prostatic Neoplasms
Sonlicromanol's active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth.
Prostatic Neoplasms
Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport.
Prostatitis
Prostaglandin levels in infertile patients affected by asthenozoospermia and prostatitis.
Proteinuria
COX-2 but not mPGES-1 contributes to renal PGE2 induction and diabetic proteinuria in mice with type-1 diabetes.
Psoriasis
Co-localization of COX-2, CYP4F8, and mPGES-1 in epidermis with prominent expression of CYP4F8 mRNA in psoriatic lesions.
Pulmonary Disease, Chronic Obstructive
The cyclooxygenase-2-prostaglandin e2 pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts.
Pulmonary Fibrosis
Microsomal prostaglandin E synthase-1 deficiency exacerbates pulmonary fibrosis induced by bleomycin in mice.
Pyometra
Identifying diagnostic endocrine markers and changes in endometrial gene expressions during pyometra in cats.
Pyometra
Positive correlation between patency and mRNA levels for cyclooxygenase-2 and prostaglandin E synthase in the uterine cervix of bitches with pyometra.
Pyometra
Prostaglandin synthesis genes are differentially transcripted in normal and pyometra endometria of bitches.
Radicular Cyst
Odontogenic cyst growth and prostaglandin-induced bone resorption.
Renal Insufficiency
Involvement of endogenous prostaglandin E2 in tubular epithelial regeneration through inhibition of apoptosis and epithelial-mesenchymal transition in cisplatin-induced rat renal lesions.
Renal Insufficiency, Chronic
Dual role of microsomal prostaglandin E synthase 1 in chronic kidney disease.
Respiratory Hypersensitivity
Deletion of Microsomal Prostaglandin E Synthase-1 Does Not Alter Ozone-induced Airway Hyper-responsiveness.
Respiratory Insufficiency
Postictal generalized EEG suppression is linked to seizure-associated respiratory dysfunction but not postictal apnea.
Rheumatic Diseases
Microsomal prostaglandin e synthase-1 in rheumatic diseases.
Rhinitis
Common household chemicals and the allergy risks in pre-school age children.
Rhinitis
Sources of propylene glycol and glycol ethers in air at home.
Sarcoma
Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials.
Scleroderma, Systemic
mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis.
Seizures
Age-specific periictal electroclinical features of generalized tonic-clonic seizures and potential risk of sudden unexpected death in epilepsy (SUDEP).
Seizures
An electroclinical case-control study of sudden unexpected death in epilepsy.
Seizures
Association between semiologic, autonomic, and electrographic seizure characteristics in children with generalized tonic-clonic seizures.
Seizures
Automated Analysis of Risk Factors for Postictal Generalized EEG Suppression.
Seizures
Automated Detection of Postictal Generalized EEG Suppression.
Seizures
Automated Video Detection of Epileptic Convulsion Slowing as a Precursor for Post-Seizure Neuronal Collapse.
Seizures
Categorisation of EEG suppression using enhanced feature extraction for SUDEP risk assessment.
Seizures
Characteristics of postictal generalized EEG suppression in children.
Seizures
Comparison of cardiorespiratory and EEG abnormalities with seizures in adults and children.
Seizures
Cortical thinning in epilepsy patients with postictal generalized electroencephalography suppression.
Seizures
Cross-Frequency Coupling Features of Postictal Generalized EEG Suppression State.
Seizures
cTnI, BNP and CRP profiling after seizures in patients with drug-resistant epilepsy.
Seizures
Cyclooxygenase-2 expression and effect of celecoxib in flurothyl-induced neonatal seizure.
Seizures
Equivocal significance of post-ictal generalized EEG suppression as a marker of SUDEP risk.
Seizures
Excitation and Inhibition Balance Underlying Epileptiform Activity.
Seizures
Ictal quantitative surface electromyography correlates with postictal EEG suppression.
Seizures
Interictal 18F-FDG brain PET metabolism in patients with postictal EEG suppression.
Seizures
Nocturnal seizures are associated with more severe hypoxemia and increased risk of postictal generalized EEG suppression.
Seizures
Peri-ictal heart rate variability parameters as surrogate markers of seizure severity.
Seizures
Periictal electroclinical characteristics of postictal generalized electroencephalographic suppression after generalized convulsive seizures.
Seizures
Post-ictal Generalized EEG Suppression is reduced by Enhancing Dorsal Raphe Serotonergic Neurotransmission.
Seizures
Postictal electroencephalographic (EEG) suppression: A stereo-EEG study of 100 focal to bilateral tonic-clonic seizures.
Seizures
Postictal generalized EEG suppression after generalized convulsive seizures: A double-edged sword.
Seizures
Postictal generalized EEG suppression and respiratory dysfunction following generalized tonic-clonic seizures in sleep and wakefulness.
Seizures
Postictal generalized EEG suppression is linked to seizure-associated respiratory dysfunction but not postictal apnea.
Seizures
Postictal generalized EEG suppression is not associated with periictal cardiac autonomic instability in people with convulsive seizures.
Seizures
Postictal generalized electroencephalographic suppression following electroconvulsive therapy: Temporal characteristics and impact of anesthetic regimen.
Seizures
Postictal generalized electroencephalographic suppression is associated with generalized seizures.
Seizures
Postictal immobility and generalized EEG suppression are associated with the severity of respiratory dysfunction.
Seizures
Postictal stertor: Associations with focal and bilateral seizure types.
Seizures
Prevention of sudden unexpected death in epilepsy: current status and future perspectives.
Seizures
Risk factors of postictal generalized EEG suppression in generalized convulsive seizures.
Seizures
Seizure Clusters, Seizure Severity Markers, and SUDEP Risk.
Seizures
The association of serotonin reuptake inhibitors and benzodiazepines with ictal central apnea.
Seizures
The SUDEP Risk Inventory: Association with postictal generalized EEG suppression.
Seizures
Tonic electromyographic activity following bilateral tonic-clonic seizures is associated with periictal respiratory dysfunction and postictal generalized EEG suppression.
Seizures
Tonic phase of a generalized convulsive seizure is an independent predictor of postictal generalized EEG suppression.
Seizures
Two predictors of postictal generalized EEG suppression: Tonic phase duration and postictal immobility period.
Seizures
Voltage-based automated detection of postictal generalized electroencephalographic suppression: Algorithm development and validation.
Sepsis
Core temperature correlates with expression of selected stress and immunomodulatory genes in febrile patients with sepsis and noninfectious SIRS.
Sepsis
Inhibition of microsomal prostaglandin E synthase-1 ameliorates acute lung injury in mice.
Silicosis
Crystalline and amorphous silica differentially regulate the cyclooxygenase-prostaglandin pathway in pulmonary fibroblasts: implications for pulmonary fibrosis.
Sinusitis
Role of prostaglandin D2 and E2 terminal synthases in chronic rhinosinusitis.
Skin Neoplasms
Gene Deletion of Microsomal Prostaglandin E Synthase-1 Suppresses Chemically Induced Skin Carcinogenesis.
Skin Neoplasms
The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis.
Skin Neoplasms
The expression pattern of prostaglandin E synthase and EP receptor isoforms in normal mouse skin and preinvasive skin neoplasms.
Sleep Apnea, Central
Prevention of sudden unexpected death in epilepsy: current status and future perspectives.
Sleep Apnea, Central
Seizure Clusters, Seizure Severity Markers, and SUDEP Risk.
Small Cell Lung Carcinoma
Characterization of the prostaglandin biosynthetic pathway in non-small cell lung cancer: a comparison with small cell lung cancer and correlation with angiogenesis, angiogenic factors and metastases.
Squamous Cell Carcinoma of Head and Neck
Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Interaction between head and neck squamous cell carcinoma cells and fibroblasts in the biosynthesis of PGE2.
Squamous Cell Carcinoma of Head and Neck
Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Prostaglandin E(2) pathway in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Simultaneous expression of cyclooxygenase-2 and microsomal prostaglandin E synthase in squamous cell carcinoma of the larynx.
Stomach Neoplasms
Clinical significance of prostaglandin E synthase expression in gastric cancer tissue.
Stomach Neoplasms
Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis.
Stomach Neoplasms
Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines.
Stomach Neoplasms
Expression of proteins related to prostaglandin E2 biosynthesis is increased in human gastric cancer and during gastric carcinogenesis.
Stomach Neoplasms
Gastric adenomas: relationship between clinicopathological findings, Helicobacter pylori infection, APC mutations and COX-2 expression.
Stomach Ulcer
Microsomal prostaglandin E synthase (mPGES)-1, mPGES-2 and cytosolic PGES expression in human gastritis and gastric ulcer tissue.
Stomach Ulcer
Role of microsomal prostaglandin E synthase-1 in the facilitation of angiogenesis and the healing of gastric ulcers.
Stomach Ulcer
The role of cyclooxygenase in gastric mucosal protection.
Stroke
Interactions among Variants in Eicosanoid Genes Increase Risk of Atherothrombotic Stroke in Chinese Populations.
Stroke
Membrane prostaglandin E synthase-1: a novel therapeutic target.
Stroke
Microsomal prostaglandin E synthase-1 and cyclooxygenase-2 are both required for ischaemic excitotoxicity.
Stroke
Microsomal prostaglandin E synthase-1 contributes to ischaemic excitotoxicity through prostaglandin E2 EP3 receptors.
Stroke
Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury.
Stroke
Molecular docking and competitive binding study discovered different binding modes of microsomal prostaglandin E synthase-1 inhibitors.
Stroke
The role of prostaglandin e2 in stroke-reperfusion injury.
Stupor
Ecotoxicological characterization of polyoxyethylene glycerol ester non-ionic surfactants and their mixtures with anionic and non-ionic surfactants.
Subarachnoid Hemorrhage
Paradoxical Increase in Mortality and Rupture of Intracranial Aneurysms in Microsomal Prostaglandin E2 Synthase Type 1-Deficient Mice: Attenuation by Aspirin.
Sudden Unexpected Death in Epilepsy
Age-specific periictal electroclinical features of generalized tonic-clonic seizures and potential risk of sudden unexpected death in epilepsy (SUDEP).
Sudden Unexpected Death in Epilepsy
An electroclinical case-control study of sudden unexpected death in epilepsy.
Sudden Unexpected Death in Epilepsy
Automated Analysis of Risk Factors for Postictal Generalized EEG Suppression.
Sudden Unexpected Death in Epilepsy
Automated detection of activity onset after postictal generalized EEG suppression.
Sudden Unexpected Death in Epilepsy
Automated Detection of Postictal Generalized EEG Suppression.
Sudden Unexpected Death in Epilepsy
Automated Video Detection of Epileptic Convulsion Slowing as a Precursor for Post-Seizure Neuronal Collapse.
Sudden Unexpected Death in Epilepsy
Autonomic changes following generalized tonic clonic seizures: An analysis of adult and pediatric patients with epilepsy.
Sudden Unexpected Death in Epilepsy
Autonomic dysregulation in children with epilepsy with postictal generalized EEG suppression following generalized convulsive seizures.
Sudden Unexpected Death in Epilepsy
Categorisation of EEG suppression using enhanced feature extraction for SUDEP risk assessment.
Sudden Unexpected Death in Epilepsy
Characteristics of postictal generalized EEG suppression in children.
Sudden Unexpected Death in Epilepsy
Cortical thinning in epilepsy patients with postictal generalized electroencephalography suppression.
Sudden Unexpected Death in Epilepsy
Detection of Postictal Generalized Electroencephalogram Suppression: Random Forest Approach.
Sudden Unexpected Death in Epilepsy
Equivocal significance of post-ictal generalized EEG suppression as a marker of SUDEP risk.
Sudden Unexpected Death in Epilepsy
Impact of periictal nurse interventions on postictal generalized EEG suppression in generalized convulsive seizures.
Sudden Unexpected Death in Epilepsy
Near SUDEP during bilateral stereo-EEG monitoring characterized by diffuse postictal EEG suppression.
Sudden Unexpected Death in Epilepsy
Nocturnal seizures are associated with more severe hypoxemia and increased risk of postictal generalized EEG suppression.
Sudden Unexpected Death in Epilepsy
Periictal autonomic dysfunction and generalized postictal EEG suppression in convulsive seizures arising from sleep and wakefulness.
Sudden Unexpected Death in Epilepsy
Periictal electroclinical characteristics of postictal generalized electroencephalographic suppression after generalized convulsive seizures.
Sudden Unexpected Death in Epilepsy
Postictal generalized EEG suppression and respiratory dysfunction following generalized tonic-clonic seizures in sleep and wakefulness.
Sudden Unexpected Death in Epilepsy
Postictal generalized EEG suppression is linked to seizure-associated respiratory dysfunction but not postictal apnea.
Sudden Unexpected Death in Epilepsy
Postictal generalized EEG suppression is not associated with periictal cardiac autonomic instability in people with convulsive seizures.
Sudden Unexpected Death in Epilepsy
Postictal generalized electroencephalographic suppression is associated with generalized seizures.
Sudden Unexpected Death in Epilepsy
Prevention of sudden unexpected death in epilepsy: current status and future perspectives.
Sudden Unexpected Death in Epilepsy
Significant postictal hypotension: Expanding the spectrum of seizure-induced autonomic dysregulation.
Sudden Unexpected Death in Epilepsy
Tonic electromyographic activity following bilateral tonic-clonic seizures is associated with periictal respiratory dysfunction and postictal generalized EEG suppression.
Sudden Unexpected Death in Epilepsy
Tonic phase of a generalized convulsive seizure is an independent predictor of postictal generalized EEG suppression.
Sudden Unexpected Death in Epilepsy
Two predictors of postictal generalized EEG suppression: Tonic phase duration and postictal immobility period.
Syncope, Vasovagal
Significant postictal hypotension: Expanding the spectrum of seizure-induced autonomic dysregulation.
Tachycardia
Characteristics of postictal generalized EEG suppression in children.
Teratoma
Characterization and multilineage differentiation of embryonic stem cells derived from a buffalo parthenogenetic embryo.
Thrombosis
An Update of Microsomal Prostaglandin E Synthase-1 and PGE2 Receptors in Cardiovascular Health and Diseases.
Thrombosis
Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury.
Thrombosis
Production of prostaglandin E2 induced by cigarette smoke modulates tissue factor expression and activity in endothelial cells.
Thyroid Cancer, Papillary
Immunohistochemical Demonstration of Membrane-bound Prostaglandin E(2) Synthase-1 in Papillary Thyroid Carcinoma.
Thyroid Neoplasms
Immunohistochemical Demonstration of Membrane-bound Prostaglandin E(2) Synthase-1 in Papillary Thyroid Carcinoma.
Triple Negative Breast Neoplasms
Kruppel-like Factor 5 Transcription Factor Promotes Microsomal Prostaglandin E2 Synthase 1 Gene Transcription in Breast Cancer.
Ureteral Obstruction
Deficiency of mPGES-1 exacerbates renal fibrosis and inflammation in mice with unilateral ureteral obstruction.
Uterine Cervical Neoplasms
COX-1 is coupled with mPGES-1 and ABCC4 in human cervix cancer cells.
Vascular Diseases
Microsomal Prostaglandin E2 Synthase-1 Deletion Attenuates Isoproterenol-Induced Myocardial Fibrosis in Mice.
Vascular Diseases
The role of prostaglandin E2 in human vascular inflammation.
Vascular System Injuries
Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1.
Vascular System Injuries
Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury.
Vascular System Injuries
Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice.
Venous Thrombosis
Prostaglandin E synthase is upregulated by Gas6 during cancer-induced venous thrombosis.
Virus Diseases
C. albicans activates cyclooxygenase but not its product prostaglandin E? in HPV 16-stabilized cells.
Virus Diseases
Transcriptomic Analysis of the Innate Antiviral Immune Response in Porcine Intestinal Epithelial Cells: Influence of Immunobiotic Lactobacilli.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0035
(2E)-2-(2,5-bis[2-[4-(trifluoromethyl)phenyl]ethoxy]benzylidene)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.01
(2E)-2-(2,5-bis[[4-(trifluoromethyl)benzyl]oxy]benzylidene)hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0034
(2E)-2-[2,5-bis(2-cyclohexylethoxy)benzylidene]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0015
(2E)-2-[2,5-bis(2-phenylethoxy)benzylidene]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.01
(2E)-2-[4-[3-(2,3-dimethylphenoxy)propoxy]benzylidene]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.01
(2E)-2-[5-(2-cyclohexylethoxy)-2-[[4-(trifluoromethyl)benzyl]oxy]benzylidene]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0042
(2R)-2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.0046
(2S)-2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.000248
(3R)-1-(7-chloro-2-[2-chloro-5-[(2-methylpropanamido)methyl]phenyl]-4-oxo-3,4-dihydroquinazolin-6-yl)pyrrolidin-3-yl acetate
Homo sapiens
pH and temperature not specified in the publication
0.000243
(3S)-1-(7-chloro-2-[2-chloro-5-[(2-methylpropanamido)methyl]phenyl]-4-oxo-3,4-dihydroquinazolin-6-yl)pyrrolidin-3-yl acetate
Homo sapiens
pH and temperature not specified in the publication
0.00372
(4R)-1-(8-chloroquinolin-2-yl)-N-[cis-4-(hydroxymethyl)cyclohexyl]-3,3-dimethylpiperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000001 - 0.000504
(4R)-N-[(1S,3S)-3-(hydroxymethyl)cyclohexyl]-3,3-dimethyl-1-[4-(trifluoromethyl)phenyl]piperidine-4-carboxamide
0.000004
(4S)-1-(8-chloroquinolin-2-yl)-N-[cis-4-(hydroxymethyl)cyclohexyl]-3,3-dimethylpiperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000007
(4S)-3,3-dimethyl-1-(8-methylquinolin-2-yl)-N-[(3S)-oxan-3-yl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000006
(4S)-3,3-dimethyl-1-(8-methylquinolin-2-yl)-N-[(3S)-oxolan-3-yl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000012
(4S)-3,3-dimethyl-N-(3-methylbutan-2-yl)-1-(8-methylquinolin-2-yl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
(4S)-N-[(1S,3S)-3-(hydroxymethyl)cyclohexyl]-3,3-dimethyl-1-[4-(trifluoromethyl)phenyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000001
(4S)-N-[(3S)-3-(hydroxymethyl)cyclohexyl]-3,3-dimethyl-1-(8-methylquinolin-2-yl)piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0051
([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)(5,8-dihydronaphthalen-1-yl)acetic acid
Homo sapiens
-
-
0.01
([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)acetic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.000002
1,5-anhydro-2,3,4-trideoxy-3-[[(4S)-3,3-dimethyl-1-(8-methylquinolin-2-yl)piperidine-4-carbonyl]amino]-D-glycero-hexitol
Homo sapiens
-
pH and temperature not specified in the publication
0.03
1-[2-(2-methylphenyl)ethyl]-4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1H-1,2,3-triazole
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.000012
1-[4-[2-(2-carboxy-2-methylpropyl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-4-yl]-2-fluorophenyl]pyridinium
Homo sapiens
-
-
0.000003
1-[5-chloro-6-(4-chlorophenyl)-1,3-benzoxazol-2-yl]-N-[(1S,3S)-3-(hydroxymethyl)cyclohexyl]piperidine-4-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0003
15-deoxy-DELTA12,14-prostaglandin J2
Homo sapiens
-
-
0.0022
2(4-(3-biphenyloxypropoxy)phenylthio)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.0011
2-(2,3-diphenethoxybenzylidene)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.000023
2-(2,6-dichloroanilino)-7,7-dimethyl-N-(2,2,2-trifluoroethyl)-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000062
2-(2,6-dichloroanilino)-7,7-dimethyl-N-(2,2,3,3,3-pentafluoropropyl)-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000041
2-(2,6-dichloroanilino)-7,7-dimethyl-N-phenyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000037
2-(2,6-dichloroanilino)-7,7-dimethyl-N-[4-(trifluoromethyl)phenyl]-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000017
2-(2,6-dichloroanilino)-7,7-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000046
2-(2,6-dichloroanilino)-7-methyl-N-[3-(trifluoromethyl)phenyl]-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000094
2-(2,6-dichloroanilino)-7-methyl-N-[4-(trifluoromethyl)phenyl]-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000013
2-(2,6-dichloroanilino)-N-(2,6-dimethylpyridin-3-yl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00001
2-(2,6-dichloroanilino)-N-(2-fluorophenyl)-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000047
2-(2,6-dichloroanilino)-N-(4,4-difluorocyclohexyl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000035
2-(2,6-dichloroanilino)-N-(4-fluorophenyl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000067
2-(2,6-dichloroanilino)-N-(6-methoxypyridin-3-yl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000058
2-(2,6-dichloroanilino)-N-[(4-fluorophenyl)methyl]-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000039
2-(2-chloro-6-fluoroanilino)-7,7-dimethyl-N-[4-(trifluoromethyl)phenyl]-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000077
2-(2-chloro-6-fluoroanilino)-N-(3-cyanophenyl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000042
2-(2-chloro-6-fluoroanilino)-N-(4-cyanophenyl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000028
2-(2-chloro-6-fluoroanilino)-N-(4-fluorophenyl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000022
2-(2-chloro-6-fluoroanilino)-N-(4-fluorophenyl)-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000021
2-(2-chloro-6-fluoroanilino)-N-(5-chloropyridin-2-yl)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000011
2-(2-chloro-6-fluoroanilino)-N-(cyclohexylmethyl)-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000008
2-(2-chloro-6-fluoroanilino)-N-[3-fluoro-5-(trifluoromethyl)phenyl]-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2,3-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00002
2-(2-chloro-6-fluoroanilino)-N-[6-(difluoromethoxy)pyridin-3-yl]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00066
2-(2-chloro-6-fluorophenyl)-4-(4-chlorophenyl)-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.00032
2-(2-chloro-6-fluorophenyl)-4-(4-phenoxyphenyl)-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.00015
2-(2-chloro-6-fluorophenyl)-4-[4-(2-phenylethyl)phenyl]-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.000008
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylethynyl)phenyl]-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.00018
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.0014
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylsulfonyl)phenyl]-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.000035
2-(2-chloro-6-fluorophenyl)-4-[4-[(E)-2-phenylethenyl]phenyl]-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.0024
2-(3,5-diphenethoxybenzyl)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0028
2-(3,5-diphenethoxybenzylidene)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0037
2-(4-bromophenyl)-5-(2-chloro-6-fluorophenyl)-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.000001 - 0.0000053
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)benzene-1,3-dicarbonitrile
0.000676
2-(difluoromethyl)-5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)benzamide
Homo sapiens
-
at pH 7.0 and 25°C
0.0000009
2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]-N-[4-methyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]pyridine-3-carboxamide
Homo sapiens
-
at pH 7.0 and 25°C
0.0000009
2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]-N-[5-methyl-4-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]pyridine-3-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.00112
2-(difluoromethyl)-N-(1H-imidazol-2-yl)-5-([[(2R)-2-methylbutanoyl]amino]methyl)benzamide
Homo sapiens
-
at pH 7.0 and 25°C
0.00246
2-(difluoromethyl)-N-(1H-imidazol-2-yl)-5-[(2-methylpropanamido)methyl]benzamide
Homo sapiens
-
at pH 7.0 and 25°C
0.0000103
2-(difluoromethyl)-N-[4-methyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]-5-(propanamidomethyl)pyridine-3-carboxamide
Homo sapiens
-
at pH 7.0 and 25°C
0.0059
2-([4,6-bis[2-(4-cyanophenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.01
2-([4,6-bis[2-(4-methoxyphenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0009
2-([4,6-bis[2-(4-methylphenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0037
2-([4,6-bis[2-(4-nitrophenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0065
2-([4,6-bis[2-(thiophen-3-yl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0039
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
Homo sapiens
-
-
0.0017
2-([4-chloro-6-[(4'-cyanobiphenyl-4-yl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
Homo sapiens
-
-
0.0021
2-([4-chloro-6-[(5-methoxy-2-methylbiphenyl-4-yl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
Homo sapiens
-
-
0.0013
2-([4-[(biphenyl-4-ylmethyl)amino]-6-chloropyrimidin-2-yl]sulfanyl)nonanoic acid
Homo sapiens
-
-
0.0029
2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.01
2-([4-[3-(2-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.0088
2-([4-[3-(2-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.01
2-([4-[3-(3-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.01
2-([4-[3-(3-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.0094
2-([4-[3-(4-chloro-2-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.0093
2-([4-[3-(4-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.0022
2-([4-[3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.01
2-([4-[3-(quinolin-6-yloxy)propoxy]phenyl]sulfanyl)hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.000198
2-bromo-5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)benzamide
Homo sapiens
-
at pH 7.0 and 25°C
0.00367
2-chloro-4-fluoro-N-(1H-imidazol-2-yl)-5-[(2-methylpropanamido)methyl]benzamide
Homo sapiens
-
at pH 7.0 and 25°C
0.000003
2-chloro-4-[(2,2-dimethylpropanamido)methyl]-N-[3-[4-(trifluoromethyl)anilino][1,2]thiazolo[4,5-b]pyridin-7-yl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.000241
2-chloro-5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)benzamide
0.000005
2-chloro-5-[(2,2-dimethylpropanamido)methyl]-N-[4-oxo-3-[4-(trifluoromethyl)phenyl]-3,4-dihydrophthalazin-6-yl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.000385
2-chloro-5-[(3,3-dimethylbutanamido)methyl]-N-(1H-imidazol-2-yl)benzamide
Homo sapiens
-
at pH 7.0 and 25°C
0.000157
2-chloro-6-fluoro-N-[3-[4-(trifluoromethyl)anilino][1,2]thiazolo[4,5-b]pyridin-7-yl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.00232
2-chloro-N-(1H-imidazol-2-yl)-4-methyl-5-[(2-methylpropanamido)methyl]benzamide
Homo sapiens
-
at pH 7.0 and 25°C
0.000885
2-chloro-N-(1H-imidazol-2-yl)-5-[(2-methylpropanamido)methyl]benzamide
Homo sapiens
-
at pH 7.0 and 25°C
0.000058
2-chloro-N-[3-(naphthalen-1-ylcarbamoyl)phenyl]benzamide
Homo sapiens
-
wild type enzyme, in 0.1 M potassium phosphate buffer, pH 7.4, 2.5 mM glutathione, at 4°C
0.0000058
2-[(3,5-dichloropyridin-4-yl)amino]-7,7-dimethyl-N-[4-(trifluoromethyl)phenyl]-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000082
2-[(3,5-dichloropyridin-4-yl)amino]-7-methyl-N-(3-methylbutyl)-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000065
2-[(3,5-dichloropyridin-4-yl)amino]-7-methyl-N-[4-(trifluoromethyl)phenyl]-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000157
2-[(3,5-dichloropyridin-4-yl)amino]-N-[(4-fluorophenyl)methyl]-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000037
2-[(3,5-dichloropyridin-4-yl)amino]-N-[2-fluoro-4-(trifluoromethyl)phenyl]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000047
2-[(3,5-dichloropyridin-4-yl)amino]-N-[4-fluoro-3-(trifluoromethyl)phenyl]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0046
2-[(3,5-diphenethoxyphenyl)thio]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.01
2-[(4,6-bis[2-[4-(trifluoromethoxy)phenyl]ethoxy]pyrimidin-2-yl)sulfanyl]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0019
2-[(4,6-bis[2-[4-(trifluoromethyl)phenyl]ethoxy]pyrimidin-2-yl)sulfanyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0012
2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0041
2-[(4-[3-[2-(propan-2-yl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.0027
2-[(4-[3-[3-(propan-2-yl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.002
2-[(4-[3-[3-(trifluoromethyl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.0017
2-[(4-[3-[4-chloro-3-(trifluoromethyl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.0026
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]nonanoic acid
Homo sapiens
-
-
0.0039
2-[2,3-bis(2-phenylethoxy)benzyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.01
2-[2,4-bis(2-phenylethoxy)benzyl]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0024
2-[2,5-bis(2-phenylethoxy)benzyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.00018
2-[2-(2-chloro-6-fluorophenyl)-4-[6-(phenylethynyl)pyridin-3-yl]-1H-imidazol-5-yl]ethanol
Homo sapiens
-
pH and temperature not specified in the publication
0.000001
2-[2-[(1S,2S)-2-([1-[4-(trifluoromethoxy)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.000002
2-[2-[(1S,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.000006
2-[2-[(1S,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]pyridine-3-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.000002
2-[2-[(1S,2S)-2-([1-[5-(trifluoromethyl)pyridin-2-yl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.000001
2-[2-[(1S,2S)-2-[[1-(8-methylquinolin-2-yl)piperidine-4-carbonyl]amino]cyclopentyl]ethyl]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.0027
2-[3,4-bis(2-phenylethoxy)benzyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0006
2-[3,5-bis(2-phenylethoxy)phenoxy]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.01
2-[3-(aminooxy)-2,2-dimethyl-3-oxopropyl]-3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indole
Homo sapiens
-
IC50: 0.01 mM
0.0014
2-[4-(4-bromophenyl)-1H-imidazol-2-yl]benzonitrile
Homo sapiens
-
pH and temperature not specified in the publication
0.001
2-[4-(4-chlorophenyl)-1H-imidazol-2-yl]-3-fluorobenzonitrile
Homo sapiens
-
pH and temperature not specified in the publication
0.005
2-[4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)phenyl]propan-2-ol
Homo sapiens
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.0071
2-[4-[3-(2,3-dimethylphenoxy)propoxy]benzyl]hexanoic acid
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.0000009
2-[6-(2-cyclopropylethoxy)-9-(3-hydroxy-3-methylbutyl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
Homo sapiens
-
-
0.006
2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid
Homo sapiens
-
-
0.0000009
2-[6-bromo-9-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
Homo sapiens
-
-
0.0000009
2-[6-chloro-9-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
Homo sapiens
-
-
0.0000007
2-[6-chloro-9-(3-hydroxy-3-methylbutyl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
Homo sapiens
-
-
0.01
2-[[4,6-bis(2-cycloheptylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0024
2-[[4,6-bis(2-cyclohexylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.01
2-[[4,6-bis(2-cyclopentylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0096
2-[[4,6-bis(2-cyclopropylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0073
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]butanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.002
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]octanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.01
2-[[4,6-bis(3-methylbutoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0022
2-[[4,6-bis(3-phenylpropoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0009
2-[[4,6-bis(4-phenylbutoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0038
2-[[4,6-bis(benzyloxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.01
2-[[4-(3-phenoxypropoxy)phenyl]sulfanyl]hexanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.0016
2-[[4-(biphenyl-4-ylamino)-6-chloropyrimidin-2-yl]sulfanyl]nonanoic acid
Homo sapiens
-
-
0.0018
3-(1-benzothiophen-2-yl)-2-bromo-5-hydroxycyclopent-2-en-1-one
Homo sapiens
-
-
0.00011
3-(4-bromophenyl)-5-(2-chloro-6-fluorophenyl)-1H-1,2,4-triazole
Homo sapiens
-
pH and temperature not specified in the publication
0.0021
3-(naphthalen-1-ylamino)-6-nitrobenzo[d]isothiazole 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.002
3-benzamidocarbazole
Homo sapiens
-
-
0.0009
3-O-acetyl-28-hydroxylupeolic acid
Homo sapiens
-
at pH 7.4 and 4°C
0.01
3-O-acetyllupeolic acid
Homo sapiens
-
at pH 7.4 and 4°C
0.0009
3-oxo-8,24-dienetirucallic acid
Homo sapiens
-
at pH 7.4 and 4°C
0.00029
3-[(5E)-3-(4-butylbenzyl)-1-(4-chlorobenzyl)-4-methylidene-5-[(2E)-4-methylpent-2-en-1-ylidene]-4,5-dihydro-1H-pyrrol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00029 mM
0.00025
3-[1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-4-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.00025
3-[1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00025 mM
0.0032
3-[1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0032 mM
0.0011
3-[1-(4-chlorobenzyl)-3-methyl-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0011 mM
0.0006
3-[1-(4-chlorobenzyl)-3-methyl-5-phenyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00060 mM
0.0043
3-[1-(4-chlorobenzyl)-3-methyl-7-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0043 mM
0.002
3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000004
3-[1-(4-chlorobenzyl)-4-(2'-chloro-2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000008
3-[1-(4-chlorobenzyl)-4-(2,2'-difluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000022
3-[1-(4-chlorobenzyl)-4-(2-chlorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000005
3-[1-(4-chlorobenzyl)-4-(2-fluoro-2'-methoxybiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000003
3-[1-(4-chlorobenzyl)-4-(2-fluoro-2'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000007
3-[1-(4-chlorobenzyl)-4-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.00065
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-phenoxy-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00065 mM
0.0064
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-phenyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0064 mM
0.0009
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-[(2-methylphenyl)carbonyl]-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00090 mM
0.000004
3-[1-(4-chlorobenzyl)-5-(2'-chloro-2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000004 mM
0.000008
3-[1-(4-chlorobenzyl)-5-(2,2'-difluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000008 mM
0.000022
3-[1-(4-chlorobenzyl)-5-(2-chlorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000022 mM
0.000005
3-[1-(4-chlorobenzyl)-5-(2-fluoro-2'-methoxybiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000005 mM
0.000003
3-[1-(4-chlorobenzyl)-5-(2-fluoro-2'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000003 mM
0.000033
3-[1-(4-chlorobenzyl)-5-(2-fluoro-3'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000033 mM
0.000031
3-[1-(4-chlorobenzyl)-5-(2-fluoro-4'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000031 mM
0.000007
3-[1-(4-chlorobenzyl)-5-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000007 mM
0.000012
3-[1-(4-chlorobenzyl)-5-(3-fluoro-4-pyridin-3-ylphenyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000012 mM
0.0026
3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0026 mM
0.000006
3-[1-(4-chlorobenzyl)-5-[2-fluoro-2'-(phenylcarbonyl)biphenyl-4-yl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000006 mM
0.000032
3-[1-(4-chlorobenzyl)-5-[3-fluoro-4-(pyrimidin-5-ylmethyl)phenyl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000032 mM
0.0016
3-[1-(p-chlorobenzvl)-5-isopropyl-3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
i.e. 3-[1-(p-chlorobenzvl)-5-isopropyl-3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid or FLAP, formerly designated L-663,536, a lipoxygenase inhibitor, IC50: 0.0016 mM
0.00006
3-[3-(benzylsulfanyl)-1-(4-chlorobenzyl)-5-[4-[(4-chloro-2-fluorophenyl)ethynyl]phenyl]-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.0021
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.0024
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.01
3-[3-(tert-butylsulfanyl)-1-methyl-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.01 mM
0.0032
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1-(3-phenylpropyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0032 mM
0.0067
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1-prop-2-en-1-yl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.0067 mM
0.01
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.01 mM
0.00026
3-[3-[(tert-butylsulfanyl)acetyl]-1-(4-chlorobenzyl)-4-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.00026
3-[3-[(tert-butylsulfanyl)acetyl]-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00026 mM
0.000006
3-[4-(2'-acetyl-2-fluorobiphenyl-4-yl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.000016
3-[4-biphenyl-4-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
-
0.01
3-[4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]propanoic acid
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.00016
3-[5-biphenyl-3-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00016 mM
0.000016
3-[5-biphenyl-4-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.000016 mM
0.00033
3-[5-tert-butyl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
-
IC50: 0.00033 mM
0.000007
3-[6-([1,1'-biphenyl]-4-yl)-1-[(4-chlorophenyl)methyl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
Homo sapiens
pH and temperature not specified in the publication
0.0004
3alpha-acetoxy-7,24-dienetirucallic acid
Homo sapiens
-
at pH 7.4 and 4°C
0.0004
3alpha-acetoxy-8,24-dienetirucallic acid
Homo sapiens
-
at pH 7.4 and 4°C
0.003
3alpha-hydroxy-7,24-dienetirucallic acid
Homo sapiens
-
at pH 7.4 and 4°C
0.0011
3alpha-hydroxy-8,24-dienetirucallic acid
Homo sapiens
-
at pH 7.4 and 4°C
0.0012
3beta-hydroxy-8,24-dienetirucallic acid
Homo sapiens
-
at pH 7.4 and 4°C
0.03
4'-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]biphenyl-4-ol
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4'-[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]biphenyl-3-ol
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4'-[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]biphenyl-4-ol
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4'-[1-[2-(2-methylphenyl)ethyl]-1H-1,2,3-triazol-4-yl]biphenyl-4-amine
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.001
4,(23)-dihydro-11-oxo-roburic acid
Homo sapiens
-
at pH 7.4 and 4°C
0.01
4,(23)-dihydronyctanthic acid
Homo sapiens
-
IC50 above 0.01 mM, at pH 7.4 and 4°C
0.01
4,(23)-dihydroroburic acid
Homo sapiens
-
IC50 above 0.01 mM, at pH 7.4 and 4°C
0.03
4-(2'-[[2-chloro-5-(trifluoromethyl)phenoxy]methyl]biphenyl-4-yl)-1-(3-phenylpropyl)-1H-1,2,3-triazole
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4-(2'-[[2-chloro-5-(trifluoromethyl)phenoxy]methyl]biphenyl-4-yl)-1-[2-(2-methylphenyl)ethyl]-1H-1,2,3-triazole
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4-(4'-phenoxybiphenyl-4-yl)-1-(3-phenylpropyl)-1H-1,2,3-triazole
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.00057
4-(4-benzylphenyl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.00039
4-(4-chlorobenzyl)-2,6-bis[4-(trifluoromethoxy)phenyl]-4H-thieno[3,2-b]pyrrole
Homo sapiens
-
-
0.00011
4-(biphenyl-4-yl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole
Homo sapiens
-
pH and temperature not specified in the publication
0.005
4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzamide
Homo sapiens
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.005
4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzoic acid
Homo sapiens
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.000043
4-chloro-2-([[(1S,2S)-2-(2,2-dimethylpropanamido)cyclopentyl]methyl]amino)benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.000004
4-chloro-2-([[(1S,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]methyl]amino)benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.000002
4-chloro-2-[([(1S,2S)-2-[(1-phenylpiperidine-4-carbonyl)amino]cyclopentyl]methyl)amino]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.000001
4-chloro-2-[2-[(1S,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.000002
4-chloro-2-[[(1R,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]methoxy]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.000001
4-fluoro-2-[2-[(1S,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.000001
4-methyl-2-[2-[(1S,2S)-2-([1-[4-(trifluoromethyl)phenyl]piperidine-4-carbonyl]amino)cyclopentyl]ethyl]benzoic acid
Homo sapiens
pH and temperature not specified in the publication
0.03
4-[(4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1H-1,2,3-triazol-1-yl)sulfonyl]benzoic acid
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1-(3-phenylpropyl)-1H-1,2,3-triazole
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4-[4-(phenanthren-9-yl)phenyl]-1-(3-phenylpropyl)-1H-1,2,3-triazole
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4-[4-benzyl-1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-5-yl]benzaldehyde
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.0032
4-[[4-(biphenyl-4-yl)-1H-1,2,3-triazol-1-yl]methyl]-3-nitrobenzoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.03
5-(4-bromophenyl)-3-(2-chloro-6-fluorophenyl)-1,2,4-oxadiazole
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.000074
5-(acetamidomethyl)-2-(difluoromethyl)-N-[4-methyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]pyridine-3-carboxamide
Homo sapiens
-
at pH 7.0 and 25°C
0.03
5-(dimethylamino)-N-[4'-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]biphenyl-4-yl]naphthalene-1-sulfonamide
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.00108
5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)-2-(trifluoromethyl)benzamide
Homo sapiens
-
at pH 7.0 and 25°C
0.00311
5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)-2-methylbenzamide
Homo sapiens
-
at pH 7.0 and 25°C
0.00094
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(1,3-thiazol-2-ylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000013
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclohex-1-en-1-ylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000033
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclohexylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.00017
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclopropylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000023
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.00048
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(pyridin-3-ylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.0025
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-ethynylpyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000009
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(2-chlorophenyl)ethynyl]pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000004
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(3-chlorophenyl)ethynyl]pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000031
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(4-chlorophenyl)ethynyl]pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.00002
5-[2-(2-chloro-6-fluorophenyl)-5-methyl-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000016
5-[5-(2-chloro-6-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-(phenylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000001
5-[5-bromo-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.000005
5-[5-chloro-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
Homo sapiens
-
pH and temperature not specified in the publication
0.0067
6-nitro-3-(m-tolylamino) benzo[d]isothiazole 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.0236
6-nitro-N-phenyl-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.05
6-nitro-N-[3-(propan-2-yl)phenyl]-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.0011
7-hydroxy-N,N'-bis(2,4,6-trimethylphenyl)naphthalene-1,3-disulfonamide
Homo sapiens
-
-
0.044
acetaminophen
Homo sapiens
-
-
0.00041
AF3442
Homo sapiens
pH and temperature not specified in the publication
0.005
aminomethyl 4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzenesulfinate
Homo sapiens
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.0003
arachidonic acid
Homo sapiens
-
-
0.0000008
biarylimidazole
Homo sapiens
-
-
0.0018
cannflavin A
Homo sapiens
-
at pH 7.4 and 4°C
0.0037
cannflavin B
Homo sapiens
-
at pH 7.4 and 4°C
0.0012
cysteinyl leukotriene LTC4
Homo sapiens
-
-
0.0003
deoxy-prostaglandin J2
Homo sapiens
-
IC50: 0.0003 mM
0.23
dyphylline
Homo sapiens
-
-
0.0003
eicosapentaenoic acid
Homo sapiens
-
-
0.01
ethyl 2-([4-[3-(quinolin-6-yloxy)propoxy]phenyl]sulfanyl)hexanoate
Homo sapiens
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.0056
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]nonanoate
Homo sapiens
-
-
0.006
licofelone
Homo sapiens
-
pH and temperature not specified in the publication
0.0085
lupeolic acid
Homo sapiens
-
at pH 7.4 and 4°C
0.0072
methyl 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoate
Homo sapiens
-
IC50: 0.0072 mM
0.005
methyl 4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzenesulfinate
Homo sapiens
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.0000017
methyl 4-[6-bromo-2-(2-chloro-6-fluorophenyl)-1H-phenanthro[9,10-d]imidazol-9-yl]but-3-ynoate
Homo sapiens
-
-
0.0000013 - 0.000003
MF63
0.0024
MK886
Homo sapiens
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4°C
0.05
N-(1,3-benzodioxol-4-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.05
N-(2-methylphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.000016
N-(3',4'-dichloro[1,1'-biphenyl]-4-yl)-4-hydroxy-1,1-dioxo-1,2-dihydro-1lambda~6~,2-benzothiazine-3-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.05
N-(3,4-dimethoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.05
N-(3-bromobenzyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4°Cn
0.0073
N-(3-bromophenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.0057
N-(3-chlorophenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.0088
N-(3-methoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.05
N-(3-tert-butylphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.000004
N-(4-chloro-2-fluorophenyl)-2-[2,6-dichloro-3-[(2,2-dimethylpropanamido)methyl]anilino]-6-(2,2-difluoroethoxy)-1-methyl-1H-benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0169
N-(4-methoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.05
N-(5-bromonaphthalen-1-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.00015
N-(6-nitro-1,1-dioxido-1,2-benzothiazol-3-yl)quinolin-5-amine
Homo sapiens
-
0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.05
N-(biphenyl-3-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
Homo sapiens
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4°C
0.0000022
N-(cyclohexylmethyl)-2-[(3,5-dichloropyridin-4-yl)amino]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000013
N-(cyclohexylmethyl)-2-[(3,5-dichloropyridin-4-yl)amino]-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000023
N-(cyclopentylmethyl)-2-(2,6-dichloroanilino)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000012
N-(cyclopropylmethyl)-2-(2,6-dichloroanilino)-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000025
N-(cyclopropylmethyl)-2-[(3,5-dichloropyridin-4-yl)amino]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000026 - 0.000058
N-([4-chloro-3-[4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazolin-2-yl]phenyl]methyl)-2-methylpropanamide
0.000481
N-([4-chloro-3-[7-chloro-4-oxo-6-(pyridin-4-yl)-3,4-dihydroquinazolin-2-yl]phenyl]methyl)-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000713
N-([4-chloro-3-[7-chloro-6-(4-hydroxypiperidin-1-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]phenyl]methyl)-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000261
N-([4-chloro-3-[7-chloro-6-(morpholin-4-yl)-4-oxo-3,4-dihydroquinazolin-2-yl]phenyl]methyl)-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000026
N-cyclohexyl-2-(2,6-dichloroanilino)-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.0000063
N-cyclohexyl-2-[(3,5-dichloropyridin-4-yl)amino]-7,7-dimethyl-7,8-dihydro-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000012
N-cyclohexyl-2-[(3,5-dichloropyridin-4-yl)amino]-7-methyl-1H-furo[3,2-e]benzimidazole-5-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000007
N-tert-butyl-1-(7-chloro-2-[2-chloro-5-[(2-methylpropanamido)methyl]phenyl]-4-oxo-3,4-dihydroquinazolin-6-yl)azetidine-3-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.000055
N-[(4-chloro-3-[4-oxo-6-[4-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.00001
N-[(4-chloro-3-[4-oxo-7-[4-(trifluoromethyl)phenyl]-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl]phenyl)methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000005 - 0.000007
N-[(4-chloro-3-[4-oxo-7-[4-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
0.000074
N-[(4-chloro-3-[4-oxo-7-[4-(trifluoromethyl)piperidin-1-yl]-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000016
N-[(4-chloro-3-[4-oxo-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000036
N-[(4-chloro-3-[7-chloro-4-oxo-6-[4-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000024
N-[(4-chloro-3-[7-chloro-6-[4-(difluoromethyl)piperidin-1-yl]-4-oxo-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000005
N-[(6-chloro-5-[4-oxo-7-[4-(trifluoromethyl)phenyl]-3,4-dihydropyrido[4,3-d]pyrimidin-2-yl]pyridin-3-yl)methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000179
N-[3-(4-bromophenyl)-4-oxo-3,4-dihydrophthalazin-6-yl]-2-chloro-6-fluorobenzamide
Homo sapiens
pH and temperature not specified in the publication
0.0013
N-[4-chloro-3-(5-methyl-1,3-benzoxazol-2-yl)phenyl]-2-(trifluoromethyl)benzamide
Homo sapiens
-
-
0.000003
N-[5-(4-chlorophenyl)-1H-imidazol-2-yl]-2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]benzamide
Homo sapiens
-
at pH 7.0 and 25°C
0.000003
N-[5-(4-chlorophenyl)-1H-imidazol-2-yl]-2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]pyridine-3-carboxamide
Homo sapiens
-
at pH 7.0 and 25°C
0.000003
N-[5-(4-chlorophenyl)-4-methyl-1H-imidazol-2-yl]-2-(difluoromethyl)-5-[(2-methylpropanamido)methyl]pyridine-3-carboxamide
Homo sapiens
-
at pH 7.0 and 25°C
0.000036
N-[[3-(7-bromo-4-oxo-3,4-dihydroquinazolin-2-yl)-4-chlorophenyl]methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000042
N-[[4-chloro-3-(7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000032
N-[[4-chloro-3-(7-chloro-6-cyclopropyl-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000111
N-[[4-chloro-3-(7-chloro-6-methoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000304
N-[[4-chloro-3-(7-methoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000063
N-[[4-chloro-3-(7-nitro-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl]methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000004
N-[[6-(difluoromethyl)-5-[4-oxo-7-[4-(trifluoromethyl)phenyl]-3,4-dihydropyrido[4,3-d]pyrimidin-2-yl]pyridin-3-yl]methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000006
N-[[6-(difluoromethyl)-5-[4-oxo-7-[4-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-2-yl]pyridin-3-yl]methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.11
Oxacillin
Homo sapiens
-
-
0.0000165
PF-9184
Homo sapiens
-
recombinant enzyme, in 100 mM K3PO4 buffer at pH 6.2
0.01
roburic acid
Homo sapiens
-
IC50 above 0.01 mM, at pH 7.4 and 4°C
0.0000195
sodium 3-[1-[(4-chlorophenyl)methyl]-5-(2-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoate
Homo sapiens
-
at pH 7.0 and 25°C
0.08
sulindac
Homo sapiens
-
0.08
sulindac sulfide
Homo sapiens
-
-
0.0034
YS121
Homo sapiens
-
pH and temperature not specified in the publication
0.03
[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]methyl benzoate
Homo sapiens
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.0012
[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl](phenyl)acetic acid
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.01
[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]acetic acid
Homo sapiens
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.000001
(4R)-N-[(1S,3S)-3-(hydroxymethyl)cyclohexyl]-3,3-dimethyl-1-[4-(trifluoromethyl)phenyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000504
(4R)-N-[(1S,3S)-3-(hydroxymethyl)cyclohexyl]-3,3-dimethyl-1-[4-(trifluoromethyl)phenyl]piperidine-4-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.000001
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)benzene-1,3-dicarbonitrile
Homo sapiens
-
-
0.000001
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)benzene-1,3-dicarbonitrile
Homo sapiens
pH and temperature not specified in the publication
0.0000053
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)benzene-1,3-dicarbonitrile
Homo sapiens
-
at pH 7.0 and 25°C
0.000241
2-chloro-5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)benzamide
Homo sapiens
-
at pH 7.0 and 25°C
0.000241
2-chloro-5-[(2,2-dimethylpropanamido)methyl]-N-(1H-imidazol-2-yl)benzamide
Homo sapiens
pH and temperature not specified in the publication
0.0000013
MF63
Homo sapiens
pH and temperature not specified in the publication
0.000003
MF63
Homo sapiens
-
pH and temperature not specified in the publication
0.0016
MK-886
Homo sapiens
-
0.0024
MK-886
Homo sapiens
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4°C
0.0032
MK-886
Homo sapiens
-
-
0.000026
N-([4-chloro-3-[4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazolin-2-yl]phenyl]methyl)-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000058
N-([4-chloro-3-[4-oxo-7-(trifluoromethyl)-3,4-dihydroquinazolin-2-yl]phenyl]methyl)-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000005
N-[(4-chloro-3-[4-oxo-7-[4-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.000007
N-[(4-chloro-3-[4-oxo-7-[4-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-2-yl]phenyl)methyl]-2-methylpropanamide
Homo sapiens
pH and temperature not specified in the publication
0.01 - 0.02
NS-398
Homo sapiens
-
COX-2 inhibitor, IC50: 0.01-0.02 mM
0.02
NS-398
Homo sapiens
-
-
0.02
NS-398
Homo sapiens
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
McNamara, D.B.; Hussey, J.L.; Kerstein, M.D.; Rosenson, R.S.; Hyman, A.L.; Kadowitz, P.J.
Modulation of prostacyclin synthetase and unmasking of PGE2 isomerase in bovine coronary arterial microsomes
Biochem. Biophys. Res. Commun.
118
33-39
1984
Bos taurus, Canis lupus familiaris, Ovis aries, Homo sapiens
brenda
Kelner, M.J.; Uglik, S.F.
Mechanism of prostaglandin E2 release and increase in PGH2/PGE2 isomerase activity by PDGF: involvement of nitric oxide
Arch. Biochem. Biophys.
321
240-243
1994
Homo sapiens
brenda
Kelner, M.J.; Uglik, S.F.
PDGF-induces the glutathione-dependent enzyme PGH2/PGE2 isomerase in NIH3T3 and pEJ transformed fibroblasts
Biochem. Biophys. Res. Commun.
198
298-303
1994
Homo sapiens
brenda
Han, R.; Tsui, S.; Smith, T.J.
Up-regulation of prostaglandin E2 synthesis by interleukin-1b in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression
J. Biol. Chem.
277
16355-16364
2002
Homo sapiens
brenda
Thoren, S.; Weinander, R.; Saha, S.; Jegerschoeld, C.; Pettersson, P.L.; Samuelsson, B.; Hebert, H.; Hamberg, M.; Morgenstern, R.; Jakobsson, P.J.
Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination
J. Biol. Chem.
278
22199-22209
2003
Homo sapiens
brenda
Jakobsson, P.J.; Thoren, S.; Morgenstern, R.; Samuelsson, B.
Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target
Proc. Natl. Acad. Sci. USA
96
7220-7225
1999
Homo sapiens (O14684), Homo sapiens
brenda
Ouellet, M.; Falgueyret, J.P.; Ear, P.H.; Pen, A.; Mancini, J.A.; Riendeau, D.; David Percival, M.
Purification and characterization of recombinant microsomal prostaglandin E synthase-1
Protein Expr. Purif.
26
489-495
2002
Homo sapiens (O14684), Homo sapiens
brenda
Vazquez-Tello, A.; Fan, L.; Hou, X.; Joyal, J.S.; Mancini, J.A.; Quiniou, C.; Clyman, R.I.; Gobeil, F.Jr.; Varma, D.R.; Chemtob, S.
Intracellular-specific colocalization of prostaglandin E2 synthases and cyclooxygenases in the brain
Am. J. Physiol.
287
R1155-R1163
2004
Homo sapiens, Rattus norvegicus, Sus scrofa
brenda
Kudo, I.; Murakami, M.
Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis
J. Biochem. Mol. Biol.
38
633-638
2005
Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Mehrotra, S.; Morimiya, A.; Agarwal, B.; Konger, R.; Badve, S.
Microsomal prostaglandin E(2) synthase-1 in breast cancer: a potential target for therapy
J. Pathol.
208
356-363
2006
Homo sapiens
brenda
Pettersson, P.L.; Thoren, S.; Jakobsson, P.J.
Human microsomal prostaglandin E synthase 1: a member of the MAPEG protein superfamily
Methods Enzymol.
401
147-161
2005
Homo sapiens
brenda
Meadows, J.W.; Pitzer, B.; Brockman, D.E.; Myatt, L.
Differential localization of prostaglandin E synthase isoforms in human placental cell types
Placenta
25
259-265
2004
Homo sapiens
brenda
Riendeau, D.; Aspiotis, R.; Ethier, D.; Gareau, Y.; Grimm, E.L.; Guay, J.; Guiral, S.; Juteau, H.; Mancini, J.A.; Methot, N.; Rubin, J.; Friesen, R.W.
Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886
Bioorg. Med. Chem. Lett.
15
3352-3355
2005
Homo sapiens
brenda
Duffy, D.M.; Seachord, C.L.; Dozier, B.L.
Microsomal prostaglandin E synthase-1 (mPGES-1) is the primary form of PGES expressed by the primate periovulatory follicle
Hum. Reprod.
20
1485-1492
2005
Homo sapiens, Macaca fascicularis (Q5DI74), Macaca fascicularis (Q6PWL5), Macaca fascicularis (Q9N0A4)
brenda
Stark, K.; Toermae, H.; Oliw, E.H.
Co-localization of COX-2, CYP4F8, and mPGES-1 in epidermis with prominent expression of CYP4F8 mRNA in psoriatic lesions
Prostaglandins Other Lipid Mediat.
79
114-125
2006
Homo sapiens
brenda
Fujikura, T.; Mukai, M.
Prostaglandin E2 synthase in syncytiotrophoblastic vesicles found in the placental intervillous space
Am. J. Obstet. Gynecol.
196
361-361
2007
Homo sapiens
-
brenda
Moon, Y.; Lee, M.; Yang, H.
Involvement of early growth response gene 1 in the modulation of microsomal prostaglandin E synthase 1 by epigallocatechin gallate in A549 human pulmonary epithelial cells
Biochem. Pharmacol.
73
125-135
2007
Homo sapiens
brenda
Yamada, T.; Takusagawa, F.
PGH2 degradation pathway catalyzed by GSH-heme complex bound microsomal prostaglandin E2 synthase type 2: the first example of a dual-function enzyme
Biochemistry
46
8414-8424
2007
Homo sapiens
brenda
St-Onge, M.; Flamand, N.; Biarc, J.; Picard, S.; Bouchard, L.; Dussault, A.; Laflamme, C.; James, M.J.; Caughey, G.E.; Cleland, L.G.; Borgeat, P.; Pouliot, M.
Characterization of prostaglandin E2 generation through the cyclooxygenase (COX)-2 pathway in human neutrophils
Biochim. Biophys. Acta
1771
1235-1245
2007
Homo sapiens
brenda
Bage, T.; Modeer, T.; Kawakami, T.; Quezada, H.C.; Yucel-Lindberg, T.
Regulation of prostaglandin E synthases: effects of siRNA-mediated inhibition of microsomal prostaglandin E synthase-1
Biochim. Biophys. Acta
1773
1589-1598
2007
Homo sapiens
brenda
Huang, X.; Yan, W.; Gao, D.; Tong, M.; Tai, H.H.; Zhan, C.G.
Structural and functional characterization of human microsomal prostaglandin E synthase-1 by computational modeling and site-directed mutagenesis
Bioorg. Med. Chem.
14
3553-3562
2006
Homo sapiens
brenda
Abdulhameed, M.D.; Hamza, A.; Liu, J.; Huang, X.; Zhan, C.G.
Human microsomal prostaglandin E synthase-1 (mPGES-1) Binding with inhibitors and the quantitative structure-activity Correlation
J. Chem. Inf. Model.
48
179-85
2008
Homo sapiens
brenda
Mosca, M.; Polentarutti, N.; Mangano, G.; Apicella, C.; Doni, A.; Mancini, F.; De Bortoli, M.; Coletta, I.; Polenzani, L.; Santoni, G.; Sironi, M.; Vecchi, A.; Mantovani, A.
Regulation of the microsomal prostaglandin E synthase-1 in polarized mononuclear phagocytes and its constitutive expression in neutrophils
J. Leukocyte Biol.
82
320-326
2007
Homo sapiens
brenda
Camacho, M.; Gerboles, E.; Escudero, J.R.; Anton, R.; Garcia-Moll, X.; Vila, L.
Microsomal prostaglandin E synthase-1, which is not coupled to a particular cyclooxygenase isoenzyme, is essential for prostaglandin E(2) biosynthesis in vascular smooth muscle cells
J. Thromb. Haemost.
5
1411-1419
2007
Homo sapiens, Homo sapiens (Q9H7Z7)
brenda
Payner, T.; Leaver, H.A.; Knapp, B.; Whittle, I.R.; Trifan, O.C.; Miller, S.; Rizzo, M.T.
Microsomal prostaglandin E synthase-1 regulates human glioma cell growth via prostaglandin E(2)-dependent activation of type II protein kinase A
Mol. Cancer Ther.
5
1817-1826
2006
Homo sapiens
brenda
Astle, S.; Newton, R.; Thornton, S.; Vatish, M.; Slater, D.M.
Expression and regulation of prostaglandin E synthase isoforms in human myometrium with labour
Mol. Hum. Reprod.
13
69-75
2007
Homo sapiens, Homo sapiens (Q9H7Z7)
brenda
Chaudhry, U.A.; Zhuang, H.; Crain, B.J.; Dore, S.
Elevated microsomal prostaglandin-E synthase-1 in Alzheimers disease
Alzheimers Dement. (N. Y.)
4
6-13
2008
Homo sapiens
brenda
Hetu, P.O.; Ouellet, M.; Falgueyret, J.P.; Ramachandran, C.; Robichaud, J.; Zamboni, R.; Riendeau, D.
Photo-crosslinking of proteins in intact cells reveals a dimeric structure of cyclooxygenase-2 and an inhibitor-sensitive oligomeric structure of microsomal prostaglandin E2 synthase-1
Arch. Biochem. Biophys.
477
155-162
2008
Homo sapiens
brenda
Kim, W.I.; Choi, K.A.; Do, H.S.; Yu, Y.G.
Expression and purification of human mPGES-1 in E. coli and identification of inhibitory compounds from a drug-library
BMB Rep.
41
808-813
2008
Homo sapiens
brenda
Frasor, J.; Weaver, A.E.; Pradhan, M.; Mehta, K.
Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines
Endocrinology
149
6272-6279
2008
Homo sapiens
brenda
Hammarberg, T.; Hamberg, M.; Wetterholm, A.; Hansson, H.; Samuelsson, B.; Haeggstroem, J.Z.
Mutation of a critical arginine in microsomal prostaglandin E synthase-1 shifts the isomerase activity to a reductase activity that converts prostaglandin H2 into prostaglandin F2{alpha}
J. Biol. Chem.
284
301-305
2009
Homo sapiens (O14684), Homo sapiens
brenda
Xing, L.; Kurumbail, R.G.; Frazier, R.B.; Davies, M.S.; Fujiwara, H.; Weinberg, R.A.; Gierse, J.K.; Caspers, N.; Carter, J.S.; McDonald, J.J.; Moore, W.M.; Vazquez, M.L.
Homo-timeric structural model of human microsomal prostaglandin E synthase-1 and characterization of its substrate/inhibitor binding interactions
J. Comput. Aided Mol. Des.
23
13-24
2009
Homo sapiens (O14684), Homo sapiens
brenda
Lee, I.Y.; Cho, W.; Kim, J.; Park, C.S.; Choe, J.
Human follicular dendritic cells interact with T cells via expression and regulation of cyclooxygenases and prostaglandin E and I synthases
J. Immunol.
180
1390-1397
2008
Homo sapiens
brenda
Friesen, R.W.; Mancini, J.A.
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target
J. Med. Chem.
51
4059-4067
2008
Homo sapiens
brenda
Koeberle, A.; Zettl, H.; Greiner, C.; Wurglics, M.; Schubert-Zsilavecz, M.; Werz, O.
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase
J. Med. Chem.
51
8068-8076
2008
Homo sapiens
brenda
Koeberle, A.; Siemoneit, U.; Buehring, U.; Northoff, H.; Laufer, S.; Albrecht, W.; Werz, O.
Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1
J. Pharmacol. Exp. Ther.
326
975-982
2008
Homo sapiens
brenda
Hamza, A.; Abdulhameed, M.D.; Zhan, C.G.
Understanding microscopic binding of human microsomal prostaglandin E synthase-1 with substrates and inhibitors by molecular modeling and dynamics simulation
J. Phys. Chem. B
112
7320-7329
2008
Homo sapiens (O14684), Homo sapiens
brenda
Jegerschoeld, C.; Pawelzik, S.C.; Purhonen, P.; Bhakat, P.; Gheorghe, K.R.; Gyobu, N.; Mitsuoka, K.; Morgenstern, R.; Jakobsson, P.J.; Hebert, H.
Structural basis for induced formation of the inflammatory mediator prostaglandin E2
Proc. Natl. Acad. Sci. USA
105
11110-11115
2008
Homo sapiens (O14684), Homo sapiens
brenda
Megias, J.; Guillen, M.I.; Clerigues, V.; Rojo, A.I.; Cuadrado, A.; Castejon, M.A.; Gomar, F.; Alcaraz, M.J.
Heme oxygenase-1 induction modulates microsomal prostaglandin E synthase-1 expression and prostaglandin E(2) production in osteoarthritic chondrocytes
Biochem. Pharmacol.
77
1806-1813
2009
Homo sapiens
brenda
Mbalaviele, G.; Pauley, A.M.; Shaffer, A.F.; Zweifel, B.S.; Mathialagan, S.; Mnich, S.J.; Nemirovskiy, O.V.; Carter, J.; Gierse, J.K.; Wang, J.L.; Vazquez, M.L.; Moore, W.M.; Masferrer, J.L.
Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor
Biochem. Pharmacol.
79
1445-1454
2010
Homo sapiens, Rattus norvegicus
brenda
Li, Y.; Angelastro, M.; Shimshock, S.; Reiling, S.; Vaz, R.J.
On the mechanism of microsomal prostaglandin E synthase type-2--a theoretical study of endoperoxide reaction with MeS-
Bioorg. Med. Chem. Lett.
20
338-340
2010
Homo sapiens
brenda
Chaudhry, U.; Zhuang, H.; Dore, S.
Microsomal prostaglandin E synthase-2: cellular distribution and expression in Alzheimers disease
Exp. Neurol.
223
359-365
2010
Homo sapiens
brenda
Hamza, A.; Tong, M.; AbdulHameed, M.D.; Liu, J.; Goren, A.C.; Tai, H.H.; Zhan, C.G.
Understanding microscopic binding of human microsomal prostaglandin E synthase-1 (mPGES-1) trimer with substrate PGH2 and cofactor GSH: insights from computational alanine scanning and site-directed mutagenesis
J. Phys. Chem. B
114
5605-5616
2010
Homo sapiens (O14684), Homo sapiens
brenda
Sveinbjoernsson, B.; Schumacher, M.C.; Hamberg, M.; Samuelsson, B.; Jakobsson, P.J.; Kogner, P.; Radmark, O.
Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells
Proc. Natl. Acad. Sci. USA
106
18757-18762
2009
Homo sapiens
brenda
Wu, T.Y.; Juteau, H.; Ducharme, Y.; Friesen, R.W.; Guiral, S.; Dufresne, L.; Poirier, H.; Salem, M.; Riendeau, D.; Mancini, J.; Brideau, C.
Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1
Bioorg. Med. Chem. Lett.
20
6978-6982
2010
Homo sapiens
brenda
Greiner, C.; Zettl, H.; Koeberle, A.; Pergola, C.; Northoff, H.; Schubert-Zsilavecz, M.; Werz, O.
Identification of 2-mercaptohexanoic acids as dual inhibitors of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1
Bioorg. Med. Chem.
19
3394-3401
2011
Homo sapiens
brenda
Lu, D.; Han, C.; Wu, T.
Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression
Gastroenterology
140
2084-2094
2011
Homo sapiens
brenda
Pawelzik, S.C.; Uda, N.R.; Spahiu, L.; Jegerschoeld, C.; Stenberg, P.; Hebert, H.; Morgenstern, R.; Jakobsson, P.J.
Identification of key residues determining species differences in inhibitor binding of microsomal prostaglandin E synthase-1
J. Biol. Chem.
285
29254-29261
2010
Homo sapiens, Rattus norvegicus
brenda
De Simone, R.; Chini, M.G.; Bruno, I.; Riccio, R.; Mueller, D.; Werz, O.; Bifulco, G.
Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase-1, 5-lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents
J. Med. Chem.
54
1565-1575
2011
Homo sapiens
brenda
Hieke, M.; Greiner, C.; Dittrich, M.; Reisen, F.; Schneider, G.; Schubert-Zsilavecz, M.; Werz, O.
Discovery and biological evaluation of a novel class of dual microsomal prostaglandin E2 synthase-1/5-lipoxygenase inhibitors based on 2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid
J. Med. Chem.
54
4490-4507
2011
Homo sapiens
brenda
Shang, E.; Wu, Y.; Liu, P.; Liu, Y.; Zhu, W.; Deng, X.; He, C.; He, S.; Li, C.; Lai, L.
Benzo[d]isothiazole 1,1-dioxide derivatives as dual functional inhibitors of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1
Bioorg. Med. Chem. Lett.
24
2764-2767
2014
Homo sapiens
brenda
Wiegard, A.; Hanekamp, W.; Griessbach, K.; Fabian, J.; Lehr, M.
Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1
Eur. J. Med. Chem.
48
153-163
2012
Homo sapiens
brenda
Sjoegren, T.; Nord, J.; Ek, M.; Johansson, P.; Liu, G.; Geschwindner, S.
Crystal structure of microsomal prostaglandin E2 synthase provides insight into diversity in the MAPEG superfamily
Proc. Natl. Acad. Sci. USA
110
3806-3811
2013
Homo sapiens (O14684), Homo sapiens
brenda
Korotkova, M.; Jakobsson, P.
Characterization of microsomal prostaglandin E synthase 1 inhibitors
Basic Clin. Pharmacol. Toxicol.
114
64-69
2014
Homo sapiens (O14684)
brenda
Banerjee, A.; Pawar, M.Y.; Patil, S.; Yadav, P.S.; Kadam, P.A.; Kattige, V.G.; Deshpande, D.S.; Pednekar, P.V.; Pisat, M.K.; Gharat, L.A.
Development of 2-aryl substituted quinazolin-4(3H)-one, pyrido[4,3-d]pyrimidin-4(3H)-one and pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as microsomal prostaglandin E2 synthase-1 inhibitors
Bioorg. Med. Chem. Lett.
24
4838-4844
2014
Homo sapiens (O14684), Homo sapiens
brenda
Kuklish, S.L.; Antonysamy, S.; Bhattachar, S.N.; Chandrasekhar, S.; Fisher, M.J.; Fretland, A.J.; Gooding, K.; Harvey, A.; Hughes, N.E.; Luz, J.G.; Manninen, P.R.; McGee, J.E.; Navarro, A.; Norman, B.H.; Partridge, K.M.; Quimby, S.J.; Schiffler, M.A.; Sloan, A.V.; Warshawsky, A.M.; York, J.S.; Yu, X.P.
Characterization of 3,3-dimethyl substituted N-aryl piperidines as potent microsomal prostaglandin E synthase-1 inhibitors
Bioorg. Med. Chem. Lett.
26
4824-4828
2016
Homo sapiens
brenda
Partridge, K.M.; Antonysamy, S.; Bhattachar, S.N.; Chandrasekhar, S.; Fisher, M.J.; Fretland, A.; Gooding, K.; Harvey, A.; Hughes, N.E.; Kuklish, S.L.; Luz, J.G.; Manninen, P.R.; McGee, J.E.; Mudra, D.R.; Navarro, A.; Norman, B.H.; Quimby, S.J.; Schiffler, M.A.; Sloan, A.V.; Warshawsky, A.M.; Weller, J.M.; Yor, Y.o.r.k.
Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1
Bioorg. Med. Chem. Lett.
27
1478-1483
2017
Homo sapiens (O14684), Homo sapiens
brenda
Muthukaman, N.; Tambe, M.; Deshmukh, S.; Pisal, D.; Tondlekar, S.; Shaikh, M.; Sarode, N.; Kattige, V.G.; Pisat, M.; Sawant, P.; Honnegowda, S.; Karande, V.; Kulkarni, A.; Behera, D.; Jadhav, S.B.; Sangana, R.R.; Gudi, G.S.; Khairatkar-Joshi, N.; Gharat, L.A.
Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors Part-1
Bioorg. Med. Chem. Lett.
27
5131-5138
2017
Homo sapiens (O14684)
brenda
Li, D.; Howe, N.; Dukkipati, A.; Shah, S.T.; Bax, B.D.; Edge, C.; Bridges, A.; Hardwicke, P.; Singh, O.M.; Giblin, G.; Pautsch, A.; Pfau, R.; Schnapp, G.; Wang, M.; Olieric, V.; Caffrey, M.
Crystallizing membrane proteins in the lipidic mesophase. Experience with human prostaglandin E2 synthase 1 and an evolving strategy
Cryst. Growth Des.
14
2034-2047
2014
Homo sapiens (O14684), Homo sapiens
brenda
Schiffler, M.A.; Antonysamy, S.; Bhattachar, S.N.; Campanale, K.M.; Chandrasekhar, S.; Condon, B.; Desai, P.V.; Fisher, M.J.; Groshong, C.; Harvey, A.; Hickey, M.J.; Hughes, N.E.; Jones, S.A.; Kim, E.J.; Kuklish, S.L.; Luz, J.G.; Norman, B.H.; Rathmell, R.E.; Rizzo, J.R.; Seng, T.W.; Thibodeaux, S.J.; Woods, T.A.
Discovery and characterization of 2-acylaminoimidazole microsomal prostaglandin E synthase-1 inhibitors
J. Med. Chem.
59
194-205
2016
Homo sapiens
brenda
Verhoff, M.; Seitz, S.; Paul, M.; Noha, S.M.; Jauch, J.; Schuster, D.; Werz, O.
Tetra- and pentacyclic triterpene acids from the ancient anti-inflammatory remedy frankincense as inhibitors of microsomal prostaglandin E2 synthase-1
J. Nat. Prod.
77
1445-1451
2014
Homo sapiens
brenda
Bahia, M.S.; Katare, Y.K.; Silakari, O.; Vyas, B.; Silakari, P.
Inhibitors of microsomal prostaglandin E2 synthase-1 enzyme as emerging anti-inflammatory candidates
Med. Res. Rev.
34
825-855
2014
Homo sapiens
brenda
Werz, O.; Seegers, J.; Schaible, A.; Weinigel, C.; Barz, D.; Koeberle, A.; Allegrone, G.; Pollastro, F.; Zampieri, L.; Grassi, G.; Appendino, G.
Cannflavins from hemp sprouts, a novel cannabinoid-free hemp food product, target microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase
PharmaNutrition
2
53-60
2014
Homo sapiens
-
brenda
Raouf, J.; Rafique, N.; Goodman, M.; Idborg, H.; Bergqvist, F.; Armstrong, R.; Jakobsson, P.; Morgenstern, R.; Spahiu, L.
Arg126 and Asp49 are essential for the catalytic function of microsomal prostaglandin E2 synthase 1 and Ser127 is not
PLoS ONE
11
e163600
2016
Homo sapiens (O14684)
brenda
Brock, J.S.; Hamberg, M.; Balagunaseelan, N.; Goodman, M.; Morgenstern, R.; Strandback, E.; Samuelsson, B.; Rinaldo-Matthis, A.; Haeggstroem, J.Z.
A dynamic Asp-Arg interaction is essential for catalysis in microsomal prostaglandin E2 synthase
Proc. Natl. Acad. Sci. USA
113
972-977
2016
Homo sapiens (O14684), Homo sapiens
brenda